<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2508200133
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIRONTA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>What VIRONTA is used for:</strong></u><br />Your doctor has prescribed these pills to help lower your cholesterol or other fats in the blood (such as triglycerides) and lower the risk of heart attacks and strokes.</p><p>&nbsp;</p><p><u><strong>What VIRONTA does:</strong></u><br />VIRONTA is the brand name for rosuvastatin that belongs to the class of medications known as &ldquo;statins&rdquo;, more specifically called HMG-CoA reductase inhibitors. HMG-CoA reductase is an enzyme involved in regulating cholesterol levels in your body.<br />Statins are used along with changes to diet and exercise to help control the amount of cholesterol produced by the body.</p><p>&nbsp;</p><p><u><strong>VIRONTA can help your body:</strong></u></p><ul><li>Decrease LDL (bad) cholesterol and triglyceride levels.</li><li>Increase HDL (good) cholesterol levels.</li><li>Decrease the Total Cholesterol/HDL-Cholesterol Ratio (TC:HDL-C Ratio). The ratio represents the balance between good and bad cholesterol.</li></ul><p>&nbsp;</p><p><strong>What is cholesterol?</strong><br />Cholesterol is one of several fatty substances in the blood that the body needs to function. And it is important to our health. Our bodies use cholesterol in a number of ways; for example, to produce bile acids that help you digest fat.</p><p>High cholesterol levels may not make you feel or look sick. However, too much cholesterol in your blood can be unhealthy; it builds up on the artery walls and can lead to the signs and symptoms of cardiovascular disease (heart disease).</p><p><u><strong>There are two very different types of cholesterol.</strong></u><br /><strong>LDL cholesterol</strong><br />If levels of LDL cholesterol are too high, they can cause the gradual build-up of cholesterol called plaque on the walls of the blood vessels. Over time, this plaque can build up so much that it narrows the arteries. Narrow arteries can slow or block blood flow to vital organs like the heart and brain. Blocked blood flow can result in a<br />heart attack or stroke.</p><p><strong>HDL cholesterol</strong><br />HDL carries the LDL cholesterol away from the blood vessel walls to the liver, where it can be removed from the body. A higher level of HDL cholesterol is good.</p><p><strong>Important cholesterol targets</strong><br />There are a few important measures that relate to your cholesterol. In addition to your HDL and LDL cholesterol, your doctor may also track your TC:HDL-C Ratio.</p><p><strong>Lowering LDL cholesterol and Ratio</strong><br />There are many things you can do, depending on your health and lifestyle, to help lower LDL cholesterol, increase HDL cholesterol and lower your TC: HDL-C Ratio. Your doctor may recommend:</p><ul><li>A change in your diet to control your weight and/or lower your cholesterol.</li><li>Exercise that is right for you.</li><li>Quitting smoking and avoiding smoky places.</li><li>Giving up alcohol or drinking less.</li></ul><p><strong>Follow your doctor&rsquo;s instructions carefully.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>When VIRONTA should not be used:</strong><br />&nbsp;</p><p><u><strong>Do not take VIRONTA if you:</strong></u></p><ul><li>Currently have liver disease.</li><li>Are pregnant or think you might be pregnant. If you become pregnant while taking VIRONTA, discontinue use immediately and discuss with your doctor, as VIRONTA should not be used by pregnant women.</li><li>Are breast-feeding.</li><li>Have ever had an allergic reaction to the active ingredient or any of the other ingredients in VIRONTA (see What the nonmedicinal ingredients are)</li><li>Are taking a drug called cyclosporine (used, for example, after organ transplant).</li><li>Have severe kidney problems</li><li>Have repeated and unexplained muscle aches or pains</li></ul><p><u><strong>In addition, do not take VIRONTA 40mg if:</strong></u></p><ul><li>You have moderate kidney problems (if in doubt, please ask your doctor)</li><li>Your thyroid gland is not working properly</li><li>You have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines</li><li>You regularly drink large amounts of alcohol</li><li>You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean or Indian).</li><li>You take other medicines called fibrates to lower your cholesterol</li></ul><p><strong>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</strong></p><p><u><strong>What the medicinal ingredient is:</strong></u><br />Rosuvastatin calcium.</p><p><u><strong>What the nonmedicinal ingredients are:</strong></u><br />colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose monohydrate, microcrystalline cellulose, magnesium stearate, ferric oxide yellow (5 mg tablets only), ferric oxide red (10 mg, 20 mg &amp; 40 mg tablets only), polyethylene glycol, titanium dioxide.<br />VIRONTA contains lactose and colouring agents but does not contain gluten.</p><p><u><strong>What dosage form it comes in:</strong></u><br />VIRONTA film-coated tablets are available in four tablet strengths:<br />5 mg, 10 mg, 20 mg, and 40 mg.</p><p><u><strong>Pregnancy:</strong></u><br />VIRONTA should not be used by pregnant women. Cholesterol compounds are essential elements for the development of a fetus. Cholesterol-lowering drugs can harm the fetus. If you become pregnant, discontinue use immediately and tell your doctor.</p><p>If you are of childbearing age, discuss with your doctor the potential risks and the importance of birth control methods.</p><p><strong>Before taking your VIRONTA tablets, tell your doctor or pharmacist if you:</strong></p><ul><li>Have thyroid problems.</li><li>Regularly drink three or more alcoholic drinks daily.</li><li>Have a family history of muscular disorders.</li><li>Had any past problems with your muscles (pain, tenderness), after using an HMG-CoA reductase inhibitor (statin) such as atorvastatin (LIPITOR&reg;), fluvastatin (LESCOL&reg;), lovastatin (MEVACOR&reg; , pravastatin (PRAVACHOL&reg;), rosuvastatin (CRESTOR&reg;) or simvastatin (ZOCOR&reg;), or have developed an allergy or intolerance to them.</li><li>Have kidney or liver problems.</li><li>Have diabetes.</li><li>Have undergone surgery or other tissue injury.</li><li>Do excessive physical exercise.</li></ul><p>Slightly increased blood sugar can occur when you take&nbsp;VIRONTA. You are likely to be at risk of developing diabetes if you have high levels of sugar and fats in your blood, are overweight and have high blood pressure. Discuss with the doctor your risk of<br />developing diabetes.</p><p>&nbsp;</p><p><u><strong>Interactions with this medication:</strong></u><br />Sometimes drugs can interact with other drugs, so tell your doctor or pharmacist if you are taking any other medications, including prescription, non-prescription and natural health products. In particular, <strong>tell your doctor if you are taking any of the following:</strong></p><ul><li>Any other cholesterol-lowering medications such as fibrates (gemfibrozil, fenofibrate), niacin or ezetimibe.</li><li>Warfarin, clopidogrel (or any other drug for thinning the blood).</li><li>Ritonavir combined with another protease inhibitor (for control of HIV infection).</li><li>Antacids (frequent use) and VIRONTA should be taken 2 hours apart.</li><li>Cyclosporin (used after organ transplant)</li><li>Fusidic acid (an antibiotic agent). Your doctor may temporarily stop your treatment of VIRONTA until the treatment with fusidic acid is complete.</li><li>Oral contraceptives (the pill) or hormone replacement therapies</li></ul><p>&nbsp;</p><p><u><strong>Driving and using machinery:</strong></u><br />Most people can drive a car and operate machinery while using VIRONTA &ndash; it will not affect their ability. However, some people feel dizzy during treatment with VIRONTA. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p><u><strong>Vironta contains lactose:</strong></u><br />If you have been told by your doctor that you have intolerance to some sugars (lactose or milk sugar), contact your doctor before taking VIRONTA.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor prescribed this medicine only for you. Do not give your medicine to anyone else because it may harm them, even if their symptoms are the same as yours.<br />Always follow your doctor&rsquo;s instructions carefully and keep taking your medicine even if you feel well.</p><ul><li>Swallow each tablet whole with a drink of water. Take VIRONTA as a single dose.</li><li>Remember to take VIRONTA at the same time every day. It does not matter if you take VIRONTA with or without food, or in the morning or evening.</li><li>Do not change the dose or stop taking the medicine without first talking to your doctor.</li><li>If you get sick, have an operation, or need medical treatment while you are taking VIRONTA, let the doctor or pharmacist know that you are taking VIRONTA.</li><li>If you have to see a different doctor, for any reason, be sure to tell him/her of any medicines you might be taking, including VIRONTA</li></ul><p><u><strong>Usual dose:</strong></u><br /><strong>Adults</strong><br />Treatment with VIRONTA is usually started with one 10 mg tablet taken once daily. Some people may be asked to start treatment with one 5 mg tablet taken once a day while others may be asked to start with one 20 mg tablet taken once a day.<br />After checking the amount of lipids in your blood, your doctor may decide to adjust your dose until you are taking the amount of VIRONTA that is right for you. The maximum daily dose is 40 mg.</p><p><strong><u>Overdose</u>:</strong><br />There is no specific treatment in the event of an overdose.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>In case of drug over dose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.</td></tr></tbody></table><p><br /><u><strong>Missed dose:</strong></u><br />Do not take a double dose. If you miss taking a tablet, take it as soon as you can. But if it is almost time for your next dose, skip the missed dose and just take the next dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Most people do not have side effects when taking VIRONTA. However, all medicines can cause unwanted side effects. These effects are usually mild and disappear after a short time.</p><p>Check with your doctor or pharmacist promptly if any of the following persist or become troublesome:</p><ul><li>Stomach pain</li><li>Headache</li><li>Constipation</li><li>Dizziness</li><li>Feeling sick</li></ul><p>Less commonly, some people may have other side effects such as a skin rash, itching and hives.</p><p>VIRONTA can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.</p><p>Possible side effects reported with some statins: breathing problems including persistent cough and/or shortness of breath or fever; confusion, poor memory, mood problems including depression; problems sleeping including insomnia and nightmares; erectile dysfunction; numbness, tingling, weakness or pain, usually<br />in your hands or feet, but this may also occur in other areas of your body (peripheral neuropathy).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td rowspan="2" colspan="2"><p><strong>Symptom/Effect</strong></p></td><td colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td rowspan="2"><p><strong>Stop taking drug and call your doctor or pharmacist</strong></p></td></tr><tr><td><p><strong>Only if severe</strong></p><p>&nbsp;</p></td><td><p><strong>In all cases</strong></p></td></tr><tr><td rowspan="8" colspan="1"><p><strong>Rare</strong></p></td><td><p>Muscle pain that you cannot explain</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle tenderness or weakness, or joint pain</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Breast enlargement in women and men (gynecomastia)</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Generalized weakness, especially if you do not feel well</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Jaundice or hepatitis symptoms like brownish or discoloured urine</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td><p>Difficulty in breathing or swallowing</p></td><td>&nbsp;</td><td>&nbsp;</td><td>✔</td></tr><tr><td><p>Allergic reaction (symptoms include swelling in the mouth, tongue, face and throat, severe itching, rash, raised lumps (hives), blistering of the skin and mucous membranes of the lips, eyes, mouth nasal passages or genitals)</p></td><td>&nbsp;</td><td>&nbsp;</td><td>✔</td></tr><tr><td><p>Liver damage: yellowing of the skin or eyes, flu-like symptoms</p></td><td>&nbsp;</td><td>&nbsp;</td><td>✔</td></tr><tr><td rowspan="2" colspan="1"><p><strong>Very rare</strong></p></td><td><p>Inflamed pancreas (pancreatitis) symptoms, such as severe stomach pain</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td><p>Memory Loss</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td rowspan="2" colspan="1"><p><strong>Unknown</strong></p></td><td><p>Increased blood sugar: frequent urination, thirst and hunger</p></td><td>✔</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Decrease of platelets in the blood (characterized by easy or excessive bleeding such as bruising easily, nosebleed and bleeding gums</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr></tbody></table><p><strong>This is not a complete list of side effects. For any unexpected effects while taking VIRONTA, contact your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Store below 30&deg;C. Protect from moisture.</li><li>KEEP YOUR TABLETS IN A SAFE PLACE where children cannot see or reach them. Your tablets could harm them.</li><li>Keep your medicine at room temperature (below 30􀀀C), away from warm or damp places like bathrooms or kitchens.</li><li>Keep your tablets in the package they came in.</li><li>If your doctor decides to stop your treatment, return your tablets to your pharmacist for disposal.</li><li>Do not take your tablets after the expiry date on the package</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What the medicinal ingredient is:</strong><br />Rosuvastatin calcium.</p><p><strong>What the nonmedicinal ingredients are:</strong><br />colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose monohydrate, microcrystalline cellulose, magnesium stearate, ferric oxide yellow (5 mg tablets only), ferric oxide red (10 mg, 20 mg &amp; 40 mg tablets only), polyethylene glycol, titanium dioxide.</p><p>VIRONTA contains lactose and colouring agents but does not contain gluten.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VIRONTA film-coated tablets are available in four tablet strengths:
5 mg, 10 mg, 20 mg, and 40 mg. They come in blister packs of 30 tablets.

VIRONTA 5mg: Each yellow, round, biconvex, film-coated tablet engraved “APO” on one side and “ROS” over “5” on the other side contains rosuvastatin calcium equivalent to 5 mg rosuvastatin

VIRONTA 10mg: Each pink, round, biconvex, film-coated tablet engraved “APO” on one side and “ROS” over “10”on the other side contains rosuvastatin calcium equivalent to 10 mg rosuvastatin.

VIRONTA 20mg: Each pink, round, biconvex, film-coated tablet engraved “APO” on one side and “ROS” over “20” on the other side contains rosuvastatin calcium equivalent to 20 mg rosuvastatin.

VIRONTA 40mg: Each pink, oval, biconvex, film-coated tablet engraved “APO” on one side and “ROS40” on the other side contains rosuvastatin calcium equivalent to 40 mg rosuvastatin.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Incorporated<br />150 Signet Drive<br />Toronto, Ontario<br />Canada, M9L 1T9<br />Tel: 1-800-268-4623, Fax: 1-800-609-9444<br />www.apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>دواعي استخدام فيرونتا:</strong></p><p>يصف لك الطبيب هذه الأقراص للمساعدة على خفض الكوليسترول أو الدهون الأخرى في الدم (مثل ثلاثي الجليسريد) وخفض احتمال الإصابة بنوبات قلبية وجلطات.</p><p>&nbsp;</p><p><strong>كيفية عمل فيرونتا:</strong><br />فيرونتا هو الاسم التجاري لمادة روسوفاستاتين التي تنتمي لفئة من الأدوية تُسمى &quot;الاستاتينات&quot;، وبمزيد من التحديد تُسمى &quot;مثبطات إنزيم مختزلة أتش أم جي سي أوه أيه&quot;. إنزيم مختزلة أتش أم جي سي أوه أيه عبارة عن إنزيم يتدخل في تنظيم مستويات الكوليسترول في الجسم. وتُستخدم الاستاتينات مع تغييرات في النظام الغذائي وممارسة الرياضة للمساعدة في ضبط نسبة الكوليسترول الذي ينتجه الجسم.</p><p>&nbsp;</p><p><strong>يساعد فيرونتا جسمك على:</strong></p><ul><li>خفض مستويات الكوليسترول منخفض الكثافة (ضار) وثلاثي الجليسريد.</li><li>زيادة مستويات الكوليسترول مرتفع الكثافة (المفيد).</li><li>خفض نسبة الكوليسترول الكلي إلى نسبة الكوليسترول مرتفع الكثافة (نسبة&quot;تي سي&quot; إلى نسبة &quot;أتش دي أل-سي&quot;). تمثل هذه النسبة التوازن بين الكوليسترول المفيد والكوليسترول الضار.</li></ul><p>&nbsp;</p><p><strong>ما المقصود بالكوليسترول؟</strong></p><p>الكوليسترول هو أحد المواد الدهنية العديدة الموجودة في الدم التي يحتاج إليها الجسم لأداء وظائفه. وهو مهم لصحتنا. تستخدم أجسامنا الكوليسترول بعدةطرق؛ على سبيل المثال لإنتاج أحماض الصفراء التي تساعد على هضم الدهون.</p><p>قد لا تشعر بالإعياء أو لا تظهر عليك أعراضه مع ارتفاع مستويات الكوليسترول. ولكن ارتفاع الكوليسترول في الدم أكثر من اللازم قد يكون له تأثير سلبي صحيًا؛ حيث إنه يتراكم على جدران الشرايين وقد يؤدي إلى أعراض وعلامات المرض القلبي الوعائي (مرض القلب).</p><p>يوجد نوعان مختلفان اختلافًا كبيرًا من الكوليسترول.</p><p>&nbsp;</p><p><strong>الكوليسترول منخفض الكثافة</strong><br />إذا كانت مستويات الكوليسترول منخفض الكثافة مرتفعة أكثر من اللازم؛ فقد تسبب تراكمًا تدريجيًا للكوليسترول - يُسمى لويحة - على جدران الأوعية الدموية. وبمرور الوقت؛ يمكن أن يزيد تراكم هذه اللويحة بحجم كبير تضيق معه الشرايين. ويمكن أن يسبب ضيق الشرايين بطء تدفق الدم أو منعه من الوصول إلى الأعضاء الحيوية في الجسم مثل القلب والدماغ. ويمكن أن يؤدي منع تدفق الدم إلى نوبة قلبية أو سكتة.</p><p>&nbsp;</p><p><strong>الكوليسترول مرتفع الكثافة</strong><br />يحمل الكوليسترول مرتفع الكثافة الكوليسترول منخفض الكثافة بعيدًا عن جدران الأوعية الدموية إلى الكبد حيث يمكن إخراجه خارج الجسم. ارتفاع مستوى الكوليسترول مرتفع الكثافة مفيد.</p><p><strong>أمور مهمة مرتبطة بالكوليسترول</strong><br />هناك بعض التدابير المهمة المرتبطة بالكوليسترول في جسمك. إضافة إلى النسبة بين الكوليسترول مرتفع الكثافة والكوليسترول منخفض الكثافة؛ سيقوم الطبيب بمراقبة نسبة &quot;تي سي&quot; إلى &quot;أتش دي أل-سي&quot;.</p><p><strong>خفض الكوليسترول منخفض الكثافة والنسبة المذكورة</strong><br />هناك أمور عديدة يمكنك القيام بها حسب صحتك ونمط حياتك للمساعدة في خفض الكوليسترول منخفض الكثافة وزيادة الكوليسترول مرتفع الكثافة وخفض نسبة &quot;تي سي&quot; إلى نسبة &quot;أتش دي أل-سي&quot;. قد يوصيك الطبيب بالأمور التالية:</p><ul><li>تغيير نظامك الغذائي لضبط وزنك و/أو خفض الكوليسترول في جسمك.</li><li>ممارسة الرياضة المناسبة لك.</li><li>الإقلاع عن التدخين والابتعاد عن الأماكن المدخنة.</li><li>الإقلاع عن الكحول أو الإقلال منه.</li></ul><p><strong>يُرجى اتباع تعليمات الطبيب بعناية.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استخدام فيرونتا:</strong><br />&nbsp;</p><p><u><strong>لا تتناول فيرونتا في الحالات التالية:</strong></u></p><ul><li>إذا كنت مصابًا بمرض في الكبد.</li><li><strong>إذا كانت المريضة حاملاً أو تظن أنها حامل.</strong> إذا حدث حمل أثناء استخدام فيرونتا؛ فيجب أن تتوقف المريضة عن استخدامه على الفور وتناقش الطبيب في هذا الشأن؛ لأنه ينبغي عدم استخدام فيرونتا للنساء الحوامل.</li><li><strong>في حالة الرضاعة الطبيعي للنساء.</strong></li><li>إذا سبق لك الإصابة بحساسية تجاه المادة الفعالة في فيرونتا أو مكوناته الأخرى (انظر القسم &quot;المكونات غير الدوائية:&quot;).</li><li>إذا كنت تستخدم عقارًا يُسمى سيكلوسبورين (يُستخدم في العلاج بعد عمليات زرع الأعضاء - على سبيل المثال).</li><li>إذا كانت لديك مشاكل حادة في الكلى</li><li>إذا كانت لديك آلام غير مبررة ومتكررة في العضلات</li></ul><p>&nbsp;</p><p><u><strong>وبالإضافة إلى ذلك، لا تأخذ فيرونتا ٤۰ ملجم في الحالات التالية:</strong></u></p><ul><li dir="rtl">لديك لمشاكل في الكلى (إذا كنت في شك، يرجى أن تسأل طبيبك)</li><li dir="rtl">لا تعمل الغدة الدرقية لديك بشكل صحيح</li><li dir="rtl">لقد كان لديك أي آلام متكررة أو غير المبررة بالعضلات، أو توجد مشاكل في العضلات في تاريخك شخصي أو العائلي ، أو تاريخ سابق من مشاكل في العضلات مع عقاقير أخرى لخفض الكوليسترول</li><li dir="rtl">إذا كنت تشرب بانتظام كميات كبيرة من الكحول</li><li>إذا كنت من أصل آسيوي (ياباني أو صيني أو فلبيني أو فيتنامي أو كوري أو هندي).</li><li dir="rtl">إذا كنت تأخذ أدوية أخرى لخفض الكولسترول&nbsp;مثل (fibrates).</li></ul><p>إذا كان أي من ذكر أعلاه ينطبق عليك (أو كنت في شك)، الرجاء العودة ومراجعة الطبيب.</p><p>&nbsp;</p><p><u><strong>المكوِّن الدوائي:</strong></u><br />روسوفاستاتين كالسيوم.</p><p><br /><u><strong>المكونات غير الدوائية المهمة:</strong></u><br />ثاني أكسيد السيليكون الغروي، كروسبوفيدون، سيلولوز هيدروكسي بروبيل، ميثيل سيلولوز هيدروكسي بروبيل، أحادي هيدرات اللاكتوز، سيلولوز دقيق البلورات، ستيرات ماغنيسيوم، أكسيد حديد أصفر (الأقراص التي تركيزها ٥ ملجم فقط)، أكسيد حديد أحمر (الأقراص التي تركيزها ۱۰ ملجم، ۲۰ ملجم و ٤۰ ملجم فقط)، جلايكول بولي ايثيلين، ثاني أكسيد التيتانيوم.<br /><strong>يحتوي فيرونتا على لاكتوز وعوامل تلوين ولا يحتوي على الجلوتين.</strong><br />&nbsp;</p><p><u><strong>الجرعات المتوفرة من هذا الدواء:</strong></u><br />تأتي أقراص فيرونتا المغلفة بطبقة رقيقة في ٤ تركيزات: ٥ ملجم, ۱۰ ملجم, ۲۰ ملجم, و ٤۰ ملجم.</p><p>&nbsp;</p><p><u><strong>الحمل:</strong></u><br />يجب عدم استخدام فيرونتا بواسطة النساء الحوامل. تُعد مركبات الكوليسترول عناصر أساسية لنمو الجنين. ويمكن أن تضر العقاقير المخفضة للكوليسترول الجنين. إذا أصبحتِ (المريضة الأنثى) حاملاً؛ فيجب عليك التوقف عن أخذ هذا الدواء على الفور واستشارة الطبيب.<br />وإذا كنتِ في سن الإنجاب؛ فاستشيري الطبيب بشأن المخاطر المتوقعة وأهمية استخدام وسائل منع الحمل.</p><p><strong>قبل أن تأخذ أقراص فيرونتا؛ ينبغي إخبار الطبيب أو الصيدلي إذا كانت تنطبق عليك إحدى الحالات التالية:</strong></p><ul><li>إذا كنت تعاني من مشكلات في الغدة الدرقية.</li><li>إذا كنت معتاد على تناول ثلاثة أكواب من مشروبات كحولية أو أكثر من ذلك بصفة يومية.</li><li>إذا كان لديك تاريخ عائلي من الإصابة باضطرابات عضلية.</li><li>إذا كنت أُصبت بمشكلات في العضلات سابقًا (ألم، مضض)، بعد استخدام أحد &quot;مثبطات إنزيم مختزلة أتش أم جي سي أوه أيه&quot; (ستاتين) مثل (&reg; لوفاستاتين (ميفاكور ،(&reg; فلوفاستاتين (ليسكول ،(&reg; أتورفاستاتين (ليبيتور أو سيمفاستاتين (&reg; روسوفاستاتين (كريستور ،(&reg; برافاستاتين (برافاكول أو أُصبت بحساسية تجاه هذه العقاقير. (&reg; (زوكور</li><li>إذا كنت مصاب بمشكلات في الكلى أو الكبد.</li><li>إذا كنت مصاب بداء السكري.</li><li>إذا كنت خضعت لعملية جراحية أو تعرضت لجرح في الأنسجة.</li><li>إذا كنت تمارس رياضة بدنية عنيفة.</li></ul><p>قد تحدث زيادة طفيفة في سكر الدم مع استخدام فيرونتا. من المحتمل تعرضك لخطر الإصابة بداء السكري إذا ارتفعت مستويات السكر والدهون في دمك وكنتِ بدينة ومصابة بضغط الدم المرتفع. ناقشي الطبيب بشأن احتمال تعرضك للإصابة بداء السكري.</p><p>&nbsp;</p><p><u><strong>التفاعلات مع هذا الدواء:</strong></u><br />أحيانًا يحدث تفاعل بين الأدوية المختلفة التي تدخل جسم الإنسان، لذا ينبغي إخبار الطبيب أو الصيدلي في حالة استخدام أي أدوية أخرى بما في ذلك الأدوية المأخوذة على أساس وصفة طبية أو بدون وصفة طبية والمنتجات الطبية الطبيعية. تحديدًا؛ <strong>يجب إخبار الطبيب إذا كنت تتناول أيًا من الأدوية التالية:</strong></p><ul><li>أي أدوية أخرى مخفضة للكوليسترول مثل الألياف (جيمفيبروزيل، فينوفيبريت)، نياسين أو إزيتايميب.</li><li>وارفارين، كلوبيدوجريل (أو أي عقار آخر لترقيق الدم).</li><li>ريتونافير بالتزامن مع مثبط بروتيز آخر (للسيطرة على عدوى فيروس نقص المناعة البشرية).</li><li>مضادات الحموضة (الاستخدام المتكرر)؛ يجب الفصل بين فيرونتا وهذه العقاقير بساعتين.</li><li>سيكلوسبورين (يُستخدم بعد عمليات زرع الأعضاء)</li><li>حمض فيوسيديك (مضاد حيوي). قد يطلب منك الطبيب إيقاف استخدام فيرونتا مؤقتًا حتى إتمام العلاج بحمض فيوسيدك.</li><li>أقراص منع الحمل أو العلاج بالهرمونات البديلة</li></ul><p>&nbsp;</p><p><u><strong>القيادة واستخدام الآلات:</strong></u><br />معظم الناس يمكنهم قيادة السيارات وتشغيل الآلات أثناء استخدام فيرونتا - انها لن تؤثر على قدرتهم. ومع ذلك، فإن بعض الناس يشعرون بالدوار أثناء العلاج مع فيرونتا. إذا كنت تشعر بالدوار، استشر طبيبك قبل محاولة القيادة أو استخدام الآلات.</p><p><u><strong>فيرونتا يحتوي على اللاكتوز</strong></u><br />إذا أخبرك طبيبك من قبل أن لديك حساسية مفرطة لبعض السكريات (اللاكتوز أو سكر الحليب)، اتصل بطبيبك قبل أخذ فيرونتا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تذكر أن الطبيب قد وصف هذا الدواء لك على وجه الخصوص. لا تعط هذا الدواء لأي شخص آخر؛ فقد يضر هذا الدواء الآخرين حتى لو كانوا يعانون من أعراض مثل التي تعاني منها.<br />اتبع تعليمات الطبيب بعناية دائمًا واستمر في أخذ الدواء حتى لو شعرت بتحسن حالتك.</p><ul><li>ابتلع كل قرص بالكامل مع كوب من الماء. خذ جرعتك من فيرونتا كجرعة فردية.</li><li>ينبغي الحرص على أخذ جرعة فيرونتا في وقت واحد محدد كل يوم. لا يهم أخذ جرعة فيرونتا مع الطعام أو بدونه أو في الصباح أو المساء.</li><li>يجب عدم تغيير الجرعة أو التوقف عن تناول الدواء قبل التحدث إلى الطبيب أولاً.</li><li>في حالة التقيؤ أو إجراء عملية جراحية أو الحاجة إلى علاج طبي أثناء استخدام فيرونتا؛ يجب إخبار الطبيب المعالج بأنك تستخدم فيرونتا.</li><li>في حالة الاضطرار إلى الذهاب إلى طبيب آخر لأي سبب؛ احرص على إخبار هذا الطبيب بالأدوية التي تستخدمها بما في ذلك فيرونتا.</li></ul><p>&nbsp;</p><p><u><strong>الجرعة العادية:</strong></u><br /><strong>البالغون</strong><br />عادة يبدأ العلاج بأقراص فيرونتا بأخذ قرص تركيز ۱۰ ملجم مرة واحدة في اليوم. قد يُطلب من بعض المرضى بدء العلاج بأخذ قرص تركيزه ٥ ملجم مرة واحدة في اليوم، في حين يُطلب من آخرين بدء العلاج بقرص تركيزه ۲۰ ملجم مرة واحدة في اليوم.<br />بعد فحص نسبة الدهون في دمك؛ قد يقرر الطبيب ضبط جرعتك حتى تأخذ الجرعة المناسبة لك من فيرونتا. الجرعة القصوى اليومية هي ٤۰ ملجم.</p><p><u><strong>الجرعة الزائدة:</strong></u><br />ليس هناك علاج محدد في حالة تناول جرعة زائدة.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>في حالة تناول جرعة زائدة من الدواء، اتصل على الفور بالطبيب أو قسم الطوارئ بالمستشفى أو بمركز مكافحة السموم الإقليمي لديك، حتى لو لم تظهر أعراض.</td></tr></tbody></table><p>&nbsp;</p><p><u><strong>الجرعة الفائتة:</strong></u><br />لا تأخذ جرعة مضاعفة. في حالة نسيان جرعة من الدواء، تناولها بمجرد أن تتذكر. ولكن إذا كان موعد الجرعة التالية قد اقترب تقريبًا، فلا تأخذ الجرعة الفائتة وتناول الجرعة التالية في موعدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>لا تحدث آثار جانبية عند معظم المرضى الذين يستخدمون فيرونتا. ولكن كل الأدوية يمكن أن تسبب آثارًا جانبية مزعجة. عادة تكون هذه الآثار الجانبية بسيطة وتزول بعد وقت قصير.<br />يجب استشارة الطبيب أو الصيدلي على الفور عند استمرار أو تفاقم الأعراض التالي:</p><ul><li>ألم في المعدة</li><li>صداع</li><li>إمساك</li><li>دوار</li><li>شعور بالغثيان</li></ul><p>في حالات أقل شيوعًا؛ قد يُصاب المرضى بآثار جانبية أخرى مثل طفح جلدي وحكة وشرى.</p><p>يمكن أن يسبب فيرونتا نتائج غير سوية في اختبارات الدم. سيقرر الطبيب المعالج موعد إجراء اختبارات الدم وسوف يشرح لك النتائج.</p><p><br />الآثار الجانبية المحتملة المبلغ عنها مع تناول العقاقير المسماة &quot;استاتينات&quot;: مشاكل التنفس بما في ذلك السعال المستمر و/ أو ضيق في التنفس أو حمى، ارتباك، ضعف الذاكرة، مشاكل في المزاج بما في ذلك الاكتئاب، مشاكل في النوم بما في ذلك الأرق والأحلام المزعجة، ضعف الانتصاب، خدر، خز، ضعف أو ألم، عادة في اليدين أو القدمين، ولكن قد يحدث هذا أيضًا في مناطق أخرى من الجسم (الاعتلال العصبي المحيطي).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td rowspan="2" colspan="2"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="8" colspan="1"><p dir="RTL"><strong>نادرة</strong></p><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">ألم عضلي غير مبرر</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">مضض عضلي أو ضعف عضلي أو ألم في<br />المفاصل</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">تضخم الثديين في النساء والرجال (تثدي الرجال)</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">ضعف عام، خصوصًا عند عدم الشعور بتحسن الحالة</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>يرقان أو أعراض التهاب الكبد مثل تلون البول باللون البني أو لون آخر.</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td><p>صعوبة في التنفس أو البلع</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>✔</p></td></tr><tr><td><p>حساسية (تشمل الأعراض تورم الفم واللسان والوجه والحلق، حكة شديدة، طفح جلدي، تورمات جلدية (شرى)، تنفط الجلد والأغشية المخاطية في الشفتين والعينين والممرات بين الفم والأنف أو الأعضاء التناسلية)</p></td><td>&nbsp;</td><td>&nbsp;</td><td>✔</td></tr><tr><td><p>تلف الكبد: اصفرار الجلد أو العينين، أعراض<br />مشابهة للأنفلونزا</p></td><td>&nbsp;</td><td>&nbsp;</td><td>✔</td></tr><tr><td rowspan="2" colspan="1"><p><strong>نادرة جدًا</strong></p></td><td><p>أعراض التهاب البنكرياس مثل ألم شديد في<br />البطن</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td><p>فقدان الذاكرة</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr><tr><td rowspan="2" colspan="1"><p><strong>غير معروفة</strong></p></td><td><p>زيادة سكر الدم: تكرار التبول، عطش وجوع</p></td><td>✔</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>نقص عدد الصفيحات في الدم (يتسم بحدوث نزيف بسيط أو مفرط مثل الإصابة بكدمات بسهولة والنزيف من الأنف ونزيف اللثة</p></td><td>&nbsp;</td><td>✔</td><td>&nbsp;</td></tr></tbody></table><p><strong>وهذه ليست كل الآثار الجانبية. في حالة حدوث أي آثار غير متوقعة أثناء استخدام فيرونتا، يجب الاتصال بالطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>تُخزن في درجة حرارة أقل من ۳۰ درجة مئوية. تُحفظ من الرطوبة.</li><li>احفظ الأقراص في مكان مأمون بعيدًا عن نظر الأطفال وأيديهم. قد تضر هذه الأقراص الأطفال.</li><li>احفظ الدواء الخاص بك في درجة حرارة الغرفة (أٌقل من ۳۰ درجة مئوية)، بعيدًا عن الأماكن الدافئة أو الرطبة مثل الحمامات أو المطابخ.</li><li>احفظ الأقراص في عبوتها الأصلية.</li><li>إذا قرر الطبيب إيقاف العلاج الذي تستخدمه؛ فأعد الأقراص إلى الصيدلي حتى يتصرف فيها.</li><li>لا تستخدم الأٌقراص بعد تاريخ انتهاء الصلاحية المكتوب على العبوة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>المكوِّن الدوائي:</strong></u><br />روسوفاستاتين كالسيوم.</p><p><u><strong>المكونات غير الدوائية المهمة:</strong></u><br />ثاني أكسيد السيليكون الغروي، كروسبوفيدون، سيلولوز هيدروكسي بروبيل، ميثيل سيلولوز هيدروكسي بروبيل، أحادي هيدرات اللاكتوز، سيلولوز دقيق البلورات، ستيرات ماغنيسيوم، أكسيد حديد أصفر (الأقراص التي تركيزها ٥ ملجم فقط)، أكسيد حديد أحمر (الأقراص التي تركيزها ۱۰ ملجم، ۲۰ ملجم و ٤۰ ملجم فقط)، جلايكول بولي ايثيلين، ثاني أكسيد التيتانيوم.</p><p><strong>يحتوي فيرونتا على لاكتوز وعوامل تلوين ولا يحتوي على الجلوتين.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>الجرعات المتوفرة من هذا الدواء:</strong></u><br />تأتي أقراص فيرونتا المغلفة بطبقة رقيقة في ٤ تركيزات: ٥ ملجم, ۱۰ ملجم, ۲۰ ملجم, و ٤۰ ملجم. تأتي الأقراص في شرائط منفطة بكل منها ۳۰ قرصًا.</p><p><br /><strong>فيرونتا ٥ ملجم:</strong> يكون كل قرص مغطى بطبقة رقيقة أصفر اللون ومستدير ومحدب من الجانبين ومنقوش على أحد جانبيه الأحرف &quot;APO&quot; وعلى الجانب الآخر الأحرف &quot;ROS&quot; على الرقم &quot; 5&quot;، ويحتوي كل قرص على مادة روسوفاستاتين تعادل ٥ ملجم من مادة روسوفاستاتين.</p><p><strong>فيرونتا ۱۰ملجم:</strong> يكون كل قرص مغطى بطبقة رقيقة قرنفلي اللون ومستدير ومحدب من الجانبين ومنقوش على أحد جانبيه الأحرف &quot;APO&quot; وعلى الجانب الآخر الأحرف &quot;ROS&quot; على الرقم &quot;10&quot;، ويحتوي كل قرص على مادة روسوفاستاتين تعادل ۱۰ ملجم من مادة روسوفاستاتين.</p><p><strong>فيرونتا ۲۰&nbsp;ملجم:</strong> يكون كل قرص مغطى بطبقة رقيقة قرنفلي اللون ومستدير ومحدب من الجانبين ومنقوش على أحد جانبيه الأحرف &quot;APO&quot; وعلى الجانب الآخر الأحرف &quot;ROS&quot; على الرقم &quot;20&quot;، ويحتوي كل قرص على مادة روسوفاستاتين تعادل ۲۰ ملجم من مادة روسوفاستاتين.</p><p><strong>فيرونتا ٤۰&nbsp;ملجم:</strong> يكون كل قرص مغطى بطبقة رقيقة قرنفلي اللون وبيضاوي ومحدب من الجانبين ومنقوش على أحد جانبيه الأحرف &quot;APO&quot; وعلى الجانب الآخر الأحرف &quot;ROS40&quot;، ويحتوي كل قرص على مادة روسوفاستاتين تعادل ٤۰ ملجم من مادة روسوفاستاتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس إنك<br />۱٥۰ سيجنت درايف<br />تورنتو، أونتاريو أم ۹ أل ۱تي ۹<br />ت: ۱۸۰۰۲٦۸٤٦۲۳ ، ف: ۱۸۰۰٦۰۹۹٤٤٤</p><p>www.apotex.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in GCC: Vironta
Trade Name in Country of Origin: Apo-Rosuvastatin
Generic Name: Rosuvastatin Calcium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Excipients:
Lactose monohydrate NF, microcrystalline cellulose NF, crospovidone NF, magnesium stearate NF, colloidal silicon dioxide NF, hydroxypropyl methylcellulose USP, hydroxypropyl cellulose NF, polyethylene glycol NF, titanium dioxide USP, red ferric oxide NF (10 mg, 20 mg & 40 mg tablets only), and yellow ferric oxide NF (5 mg tablets only).
See 6.1 for details.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets of 5,10, 20 & 40mg strengths.
5 mg
Yellow round, biconvex, film-coated tablet, engraved ―APO‖ on one side, ―ROS‖ over ―5‖ on the
other side.
10 mg
Pink, round, biconvex, film-coated tablet. Engraved ―APO‖ on one side, ―ROS‖ over ―10‖ on the
other side.
20 mg
Pink, round, biconvex, film-coated tablet. Engraved ―APO‖ on one side, ―ROS‖ over ―20‖ on the
other side.
40 mg
Pink, oval, biconvex, film-coated tablet, engraved "APO" on one side, "ROS40" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypercholesterolemia </strong></p><p><strong>Adults</strong></p><p><strong>APO-ROSUVASTATIN </strong>(rosuvastatin calcium) is indicated as an adjunct to diet, at least equivalent to the Adult Treatment Panel III (ATP III TLC diet), for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C; in hyperlipidemic and dyslipidemic conditions, when response to diet and exercise alone has been inadequate including:</p><ul><li>Primary hypercholesterolemia (Type IIa including severe non-familial hypercholesterolemia)</li><li>Combined (mixed) dyslipidemia (Type IIb)</li><li>Homozygous familial hypercholesterolemia where APO-ROSUVASTATIN is used either alone or as an adjunct to diet and other lipid lowering treatments such as apheresis.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be placed on a standard cholesterol-lowering diet (at least equivalent to the Adult Treatment Panel III (ATP III TLC diet)) before receiving APO-ROSUVASTATIN (rosuvastatin calcium), and should continue on this diet during treatment with APO-ROSUVASTATIN. If appropriate, a program of weight control and physical exercise should be implemented.</p><p>Prior to initiating therapy with APO-ROSUVASTATIN, secondary causes for elevations in plasma lipid levels should be excluded. A lipid profile should also be performed.</p><p>APO-ROSUVASTATIN may be taken in the morning or evening, with or without food.</p><p>&nbsp;</p><p><strong>Recommended Dose and Dosage Adjustment </strong></p><p><strong>Adults</strong></p><p><strong>Hypercholesterolemia</strong></p><p>The dose range of APO-ROSUVASTATIN is 5 to 40 mg orally once a day. The recommended starting dose of APO-ROSUVASTATIN in most patients is 10 mg orally once daily. The majority of patients are controlled at the 10 mg dose. If necessary, dose adjustment can be made at 2-4 week intervals. The maximum response is usually achieved within 2-4 weeks and is maintained during chronic therapy.</p><p>Initiation of therapy with APO-ROSUVASTATIN 5 mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy (see 4.4, Muscle Effects).</p><p>Patients who are switched to APO-ROSUVASTATIN from treatment with another HMG-CoA reductase inhibitor should be started on 10 mg even if they were on a high dose of the previous HMGCoA reductase inhibitor. A switch dose of 20 mg may be considered for patients with severe hypercholesterolemia.</p><p>For patients with severe hypercholesterolemia (including those with familial hypercholesterolemia), a 20 mg start dose may be considered. These patients should be carefully followed.</p><p>A dose of 40 mg once daily should only be used in patients with severe hypercholesterolemia who do not achieve the desired effect on 20 mg and have no predisposing factors for myopathy/rhabdomyolysis (see 4.3). Consultation with a specialist is recommended when initiating APO-ROSUVASTATIN 40 mg dose.</p><p>The dosage of APO-ROSUVASTATIN should be individualized according to baseline LDL-C, total C/HDL-C ratio and/or TG levels to achieve the recommended desired lipid values at the lowest possible dose.</p><p>&nbsp;</p><p><strong><u>Dosing Considerations in Special Populations.</u></strong></p><p><strong>Patients</strong><strong> with Hepatic Impairment:</strong></p><p>The usual dose range applies in patients with mild to moderate hepatic impairment. Increased systemic exposure has been observed in patients with severe hepatic impairment and, therefore, in these patients the dose of APO-ROSUVASTATIN should not exceed 20 mg once daily (see 4.3 and 4.4, Hepatic/ Biliary/Pancreatic, Hepatic Impairment).</p><p>&nbsp;</p><p><strong>Patients with Renal Impairment:</strong></p><p>The usual dose range applies in patients with mild to moderate renal impairment. Increased systemic exposure to rosuvastatin has been observed in patients with severe renal impairment. For patients with severe renal impairment (creatinine clearance &lt; 30 mL/min/l.73 m2) the starting dose of APO-ROSUVASTATIN should be 5 mg and not exceed 10 mg once daily (see 4.3 and 4.4, Renal, Renal Impairment).</p><p>&nbsp;</p><p><strong>Race:</strong></p><p>The initial dose of APO-ROSUVASTATIN, in Asian patients, should be 5 mg once daily. The potential for increases in systemic exposure must be considered when making treatment decisions. The maximum dose should not exceed APO-ROSUVASTATIN 20 mg once daily (see 4.3 and 4.4, Special Populations, Race).</p><p>Apo-Rosuvastatin is not for use in children and adolescent less than 18 years of age.</p><p>&nbsp;</p><p><strong>Use in Elderly:</strong></p><p>No dose adjustment is necessary in the elderly (see 4.4, Special Populations, Geriatrics).</p><p>&nbsp;</p><p><strong>Genetic polymorphisms:</strong></p><p>Genotypes of SLCO1B1 (OATP1B1) c.521CC and ABCG2 (BCRP) c.421AA have been shown to be associated with an increase in rosuvastatin exposure (AUC) compared to SLCO1B1 c.521TT and ABCG2 c.421CC.&nbsp; For patients known to have the c.521CC or c.421AA genotype, a maximum once daily dose of 20 mg of APO-ROSUVASTATIN is recommended (see 4.4, 4.5 and 5.2, Special Populations and Conditions).</p><p>&nbsp;</p><p><strong>Concomitant Therapy:</strong></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when APO-ROSUVASTATIN is administered concomitantly with certain medicines that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. cyclosporine and certain protease inhibitors including combinations of ritonavir with atazanavir, darunavir, lopinavir, and/or tipranavir, see 4.5).&nbsp; Whenever possible, alternative medications should be considered, and if necessary, consider temporarily discontinuing Rosuvastatin calcium therapy. &nbsp;In situations where coadministration of these medicines with APO-ROSUVASTATIN is unavoidable, the benefit and the risk of concurrent treatment and Rosuvastatin calcium dosing adjustments should be carefully considered (see 4.4 and 5.2, Special Populations and Conditions).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ROSUVASTATIN (rosuvastatin calcium) is contraindicated:

• In patients who are hypersensitive to any component of this medication (see 6.1).
• In patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal (see 4.4).
• In pregnant and nursing women.

Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). APO-ROSUVASTATIN should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the possible harm. If the patient becomes pregnant while taking APO-ROSUVASTATIN, the drug should be discontinued immediately and the patient apprised of the potential harm to the fetus. Atherosclerosis being a chronic process, discontinuation of lipid metabolism regulating drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia (see 4.4, Special Populations, Pregnant Women, Nursing Women).

• In patients using concomitant cyclosporine (see 4.5). 

APO-ROSUVASTATIN 40 mg is contraindicated in:

• Asian patients
• Patients with pre-disposing factors for myopathy/rhabdomyolysis such as:
• Personal or family history of hereditary muscular disorders
• Previous history of muscle toxicity with another HMG-CoA reductase inhibitor
• Concomitant use of a fibrate or niacin
• Severe hepatic impairment
• Severe renal impairment (CrCl < 30 mL/min/1.73 m2) (see 4.2, Patients with Renal Impairment)
• Hypothyroidism
• Alcohol abuse
• Situations where an increase in rosuvastatin plasma levels may occur (see 4.5 and 5.2, Special Populations and Conditions).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>Before instituting therapy with APO-ROSUVASTATIN (rosuvastatin calcium), an attempt should be made to control hypercholesterolemia with appropriate diet, exercise, weight reduction in overweight patients and to treat other underlying medical problems and associated cardiovascular risk factors. The patient should be advised to inform subsequent physicians of the prior use of APO-ROSUVASTATIN or any other lipid-lowering agent.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong></p><p><strong>Co-enzyme </strong><strong>Q</strong><strong>10 </strong><strong>(ubiquinone)</strong></p><p>Ubiquinone levels were not measured in rosuvastatin calcium clinical trials. Significant decreases in circulating ubiquinone levels in patients treated with other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure (see REFERENCES).</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p><strong>Endocrine Function</strong></p><p>HMG-CoA reductase inhibitors interfere with cholesterol synthesis and lower cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production.</p><p>Rosuvastatin demonstrated no effect upon nonstimulated cortisol levels and no effect on thyroid metabolism as assessed by TSH plasma concentration. In rosuvastatin calcium treated patients, there was no impairment of adrenocortical reserve and no reduction in plasma cortisol concentrations. Clinical studies with other HMG-CoA reductase inhibitors have suggested that these agents do not reduce plasma testosterone concentration. The effects of HMG-CoA reductase inhibitors on male fertility have not been studied. The effects, if any, on the pituitary- gonadal axis in premenopausal women are unknown.</p><p>Patients treated with rosuvastatin who develop clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients receiving other drugs (e.g. ketoconazole, spironolactone or cimetidine) that may decrease the levels of endogenous steroid hormones.</p><p>&nbsp;</p><p><strong>Plasma Glucose</strong></p><p>Increases in fasting glucose and HbA1c levels have been reported with inhibitors of HMG-CoA reductase as a class.&nbsp; For some patients, at high risk of diabetes mellitus, hyperglycemia was sufficient to shift them to the diabetes status.&nbsp; The benefit of treatment continues to outweigh the small increased risk. Periodic monitoring of these patients is recommended.</p><p>In the JUPITER trial, rosuvastatin 20 mg was observed to increase plasma glucose levels, which were sufficient to shift some prediabetic subjects to the diabetes mellitus status (see 4.8).</p><p>&nbsp;</p><p><strong>Lipoprotein(a)</strong></p><p>In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease. It is thus desirable to maintain and reinforce lifestyle changes in high risk patients placed on rosuvastatin therapy.</p><p>&nbsp;</p><p><strong><u>Hepatic/Biliary/Pancreatic</u></strong></p><p><strong>Hepatic Effects</strong></p><p><strong>APO-ROSUVASTATIN</strong><strong> is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.</strong></p><p>As with other HMG-CoA reductase inhibitors, it is recommended that a liver function test be carried out prior to, and 3 months following, the initiation of APO-ROSUVASTATIN or if the patient is titrated to the dose of 40 mg. APO-ROSUVASTATIN should be discontinued or the dose reduced if the level of transaminases is greater than 3 times the upper limit of normal.</p><p>APO-ROSUVASTATIN, as well as other HMG-CoA reductase inhibitors should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease.</p><p>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin (&lt; 0.5%); the majority of cases were mild, asymptomatic and transient.</p><p>There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin (see 4.8, Post-Market Adverse Drug Reactions). &nbsp;If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with APO-ROSUVASTATIN, promptly interrupt therapy. &nbsp;If an alternate etiology is not found, do not restart APO-ROSUVASTATIN.</p><p>&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>In subjects with varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin other than in 2 subjects with the most severe liver disease (Child-Pugh scores of 8 and 9). In these subjects, systemic exposure was increased by at least 2-fold compared to subjects with lower Child-Pugh scores (see 4.2, Patients with Hepatic Impairment).</p><p>&nbsp;</p><p><strong>Muscle Effects</strong></p><p><strong>Rare </strong><strong>cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with rosuvastatin calcium and with other HMG-CoA reductase inhibitors.</strong></p><p>Effects on skeletal muscle such as myalgia, myopathy and, rarely, rhabdomyolysis have been reported in patients treated with rosuvastatin calcium at all doses and in particular with the 40 mg dose.</p><p>Myopathy, defined as muscle pain or muscle weakness in conjunction with increases in creatine kinase (CK) values to greater than ten times the upper limit of normal, should be considered in any patient with diffuse myalgias, muscle tenderness or weakness and/or marked elevation of CK. Patients should be advised to report promptly any unexplained muscle pain, tenderness or weakness, particularly if associated with malaise or fever. Patients who develop any signs or symptoms suggestive of myopathy should have their CK levels measured. Rosuvastatin calcium therapy should be discontinued if markedly elevated CK levels (&gt; 10 x ULN) are measured or myopathy is diagnosed or suspected.&nbsp; There have been very rare reports of an immune-mediated necrotizing myopathy clinically characterized by persistent proximal muscle weakness and elevated serum creatine kinase during treatment or following discontinuation of statins, including rosuvastatin. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required.</p><p>&nbsp;</p><p><u>Pre-disposing Factors for Myopathy/Rhabdomyolysis</u></p><p>APO-ROSUVASTATIN, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><ul><li>Personal or family history of hereditary muscular disorders</li><li>Previous history of muscle toxicity with another HMG-CoA reductase inhibitor</li><li>Concomitant use of a fibrate or niacin</li><li>Hypothyroidism</li><li>Alcohol abuse</li><li>Excessive physical exercise</li><li>Age &gt; 70 years</li><li>Renal impairment</li><li>Hepatic impairment</li><li>Diabetes with hepatic fatty change</li><li>Surgery and trauma</li><li>Frailty</li><li>Situations where an increase in plasma levels of rosuvastatin may occur (see 4.5 and 5.2, Special Populations and Conditions).</li></ul><p>&nbsp;</p><p>In rosuvastatin calcium trials there was no evidence of increased skeletal muscle effects when rosuvastatin calcium was dosed with concomitant therapy such as fibric acid derivatives (including fenofibrate and gemfibrozil), nicotinic acid, azole antifungals and macrolide antibiotics. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with these medicines.</p><p>Rosuvastatin calcium therapy should be temporarily withheld or discontinued in any patient with an acute serious condition suggestive of myopathy or predisposing to the development of rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic endocrine and electrolyte disorders, or uncontrolled seizures).</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p><strong>Renal</strong><strong> Impairment</strong></p><p>Subjects with severe renal impairment (CrCl &lt; 30 mL/min/l .73m2) had a 3-fold increase in plasma concentration of rosuvastatin compared to healthy volunteers and, therefore, rosuvastatin calcium 40 mg is contraindicated in these patients (see 4.3 and 4.2, Patients with Renal Impairment).</p><p>In subjects with varying degrees of renal impairment, mild to moderate renal disease had little influence on plasma concentrations of rosuvastatin.</p><p>During the clinical development program, dipstick-positive proteinuria and microscopic hematuria were observed among rosuvastatin-treated patients, predominantly in patients dosed above the recommended dose range (i.e. 80 mg). Abnormal urinalysis testing (dipstick-positive proteinuria) has been seen in patients taking rosuvastatin calcium and other HMG-CoA reductase inhibitors. This finding was more frequent in patients taking 40 mg when compared to lower doses of rosuvastatin or comparator statins. Shifts in urine protein from none or trace to ++ (dipstick) or more were seen in &lt; 1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. The protein detected was mostly tubular in origin. In most cases, proteinuria was generally transient and it decreased or disappeared spontaneously on continued therapy. It has not been shown to be predictive of acute or progressive renal disease.</p><p>Nevertheless, a dose reduction may be considered for patients with unexplained persistent proteinuria during routine testing.</p><p>&nbsp;</p><p><strong><u>Sensitivity/Resistance</u></strong></p><p><strong>Hypersensitivity</strong></p><p>An apparent hypersensitivity syndrome has been reported rarely with other HMG-CoA reductase inhibitors. This has included one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive antinuclear antibody (ANA), erythrocyte sedimentation rate (ESR) increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis and erythema multiforme including Stevens-Johnson syndrome. Treatment should be discontinued if hypersensitivity is suspected (see 4.3).</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p><strong>Pregnant</strong><strong> Women:</strong></p><p><strong>APO-ROSUVASTATIN</strong><strong> is contraindicated during pregnancy (see 4.3). Nursing Women:</strong></p><p>It is not known whether rosuvastatin is excreted in human milk. Because of the potential for adverse reactions in nursing infants, women taking APO-ROSUVASTATIN should not breast-feed (see 4.3).</p><p>&nbsp;</p><p><strong><u>Apo-Rosuvastatin is not for use in children and adolescent less than 18 years of age.</u></strong></p><p><strong>Geriatrics</strong><strong> (&ge; 65 years of age):</strong></p><p>There were no clinically significant pharmacokinetic differences between young and elderly patients (&ge; 65 years) (see 4.2, Use in Elderly). However, elderly patients may be more susceptible to myopathy (see 4.4, Muscle Effects, Pre-disposing Factors for Myopathy/Rhabdomyolysis).</p><p>&nbsp;</p><p><strong>Race:</strong></p><p>Results of pharmacokinetic studies, including a large study conducted in North America, have demonstrated an approximate 2-fold elevation in median exposure in Asian subjects (having either Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin) when compared with a Caucasian control group. This increase should be considered when making rosuvastatin dosing decisions for Asian patients and the dose of 40 mg is contraindicated in these patients (see 5.2, Special Populations and Conditions, 4.3 and 4.2, Race).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p>In rosuvastatin calcium clinical trials there was no evidence of increased skeletal muscle effects when rosuvastatin was dosed with any concomitant therapy. However, rosuvastatin calcium and other HMG-CoA reductase inhibitors may cause dose-related increases in serum transaminases and CK levels. An increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors with cyclosporine, fibric acid derivatives (including gemfibrozil), nicotinic acid, azole antifungals and macrolide antibiotics.</p><p>&nbsp;</p><p><strong>Cytochrome P450 Inhibitors</strong></p><p><em>In vitro </em>and <em>in vivo </em>data indicate that rosuvastatin has no clinically significant cytochrome P450 interactions (as substrate, inhibitor or inducer). Consequently, there is little potential for drug- drug interactions upon coadministration with agents that are metabolised by cytochrome P450. Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 2C9, 2C19 and 3A inhibitors (ketoconazole, fluconazole).</p><p>&nbsp;</p><p><strong>Transporter Protein Inhibitors</strong></p><p>Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP.&nbsp; Concomitant administration of Rosuvastatin calcium with medicines that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see 4.4, 4.2, Dosing Considerations in Special Populations and 4.5, Drug-Drug Interactions (Table 3)).</p><p>&nbsp;</p><p><strong>Concomitant Therapy with Other Lipid Metabolism Regulators</strong></p><p>Coadministration of fenofibrate and rosuvastatin calcium 10 mg did not lead to a clinically significant change in the plasma concentrations of either drug. In addition, neither myopathy nor marked CK elevations (&gt;10 x ULN) were observed in a study of 128 patients who received rosuvastatin calcium 10, 20 and 40 mg plus extended-release niacin or in a second study of 103 patients who received rosuvastatin calcium 5 and 10 mg plus fenofibrate. Based on the above data, no pharmacokinetic or pharmacodynamic interaction was observed. No data is available with other fibrates.</p><p>Based on post-marketing surveillance, gemfibrozil, fenofibrate, other fibrates and lipid lowering doses of niacin (nicotinic acid) may increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone (see 4.4, Muscle Effects, Pre-disposing Factors for Myopathy/Rhabdomyolysis).</p><p>Therefore, combined drug therapy should be approached with caution.</p><p>&nbsp;</p><p><strong>Concomitant Therapies Without Clinically Significant Interactions</strong></p><p><strong>Bile Acid Sequestrants: </strong>Rosuvastatin calcium can be used in combination with bile acid sequestrant (e.g. cholestyramine).</p><p><strong>Ezetimibe</strong>: Coadministration of ezetimibe with Rosuvastatin calcium resulted in a 19% increase in the AUC of rosuvastatin. This small increase is not considered clinically significant.</p><p><strong>Ketoconazole: </strong>Coadministration of ketoconazole with rosuvastatin calcium resulted in no change in plasma concentrations of rosuvastatin.</p><p><strong>Erythromycin: </strong>Coadministration of erythromycin with rosuvastatin calcium resulted in small decreases in plasma concentrations of rosuvastatin. These reductions were not considered clinically significant.</p><p><strong>Fluconazole: </strong>Coadministration of fluconazole with rosuvastatin calcium resulted in a 14% increase in the AUC of rosuvastatin. This small increase is not considered clinically significant.</p><p><strong>Digoxin: </strong>Coadministration of digoxin and rosuvastatin calcium did not lead to any clinically significant interactions.</p><p><strong>Rifampin: </strong>Coadministration of rifampin with Rosuvastatin calcium resulted in no change in plasma concentrations of rosuvastatin.</p><p><strong>Other Drugs: </strong>Although specific interaction studies were not performed, rosuvastatin calcium has been studied in over 5300 patients in clinical trials. Many patients were receiving a variety of medications including antihypertensive agents (beta-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and diuretics), antidiabetic agents (biguanides, sulfonylureas, alpha glucosidase inhibitors, and thiazolidinediones), and hormone replacement therapy without evidence of clinically significant adverse interactions.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p>The drugs listed in Table 3 are based on either drug interaction case reports or studies or potential interactions due to the expected magnitude and seriousness of the interaction (i.e. those identified as contraindicated).</p><p>&nbsp;</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Established or Potential Drug-Drug Interactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper </strong><strong>Name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical Comment</strong></p></td></tr><tr><td><p>Immunosuppressants (Including Cyclosporine)</p></td><td><p>Rosuvastatin calcium 10 and 20 mg were administered to cardiac transplant patients (at least 6 months post- transplant) whose concomitant medication included cyclosporine, prednisone and azathioprine. Results showed that cyclosporine pharmacokinetics were not affected by rosuvastatin.</p><p>However, cyclosporine did increase the systemic exposure of rosuvastatin by 11-fold (Cmax) and 7.1-fold (AUC [0-24]) compared with historical data in healthy individuals.</p></td><td><p>The concomitant use of rosuvastatin calcium and cyclosporine is contraindicated (see 4.3).</p></td></tr><tr><td><p>Protease Inhibitors</p></td><td><p>Coadministration of Rosuvastatin calcium with various protease inhibitors in combination with ritonavir to healthy volunteers resulted in the following changes to rosuvastatin plasma levels:</p><p><strong>&nbsp;</strong></p><p>Atazanavir 300 mg/ritonavir 100 mg (OD, 8 days), Rosuvastatin calcium 10 mg (single dose); approximately a 3.1-fold increase in rosuvastatin mean AUC(0-24)</p><p>Lopinavir 400 mg/ritonavir 100 mg (BID, 17 days), Rosuvastatin calcium 20 mg (OD, 7 days); approximately a 2.1-fold increase in rosuvastatin mean AUC(0-24)</p><p>&nbsp;</p><p>Darunavir 600 mg/ritonavir 100 mg (BID, 7 days), Rosuvastatin calcium 10 mg (OD, 7 days); approximately a 1.5-fold increase in rosuvastatin mean AUC(0-24)</p><p>&nbsp;</p><p>Tipranavir 500 mg/ritonavir 200 mg (BID, 11 days), Rosuvastatin calcium 10 mg (single dose); approximately a 1.4-fold increase in rosuvastatin mean AUC(0-24)</p><p>&nbsp;</p><p>Fosamprenavir 700 mg/ritonavir 100 mg (OD, 8 days), Rosuvastatin calcium 10 mg (single dose); no significant change in rosuvastatin mean AUC(0-24)</p></td><td><p>For co-administration with atazanavir/ritonavir, the dose of rosuvastatin should not exceed 10 mg daily. For co-administration with lopinavir/ritonavir, darunavir/ritonavir or tipranavir/ritonavir, the dose of rosuvastatin should not exceed 20 mg daily.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper </strong><strong>Name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical Comment</strong></p></td></tr><tr><td><p>Gemfibrozil</p></td><td><p>Coadministration of a single rosuvastatin dose (10 mg) to healthy volunteers on gemfibrozil (600 mg bid) resulted in a 2.2 and 1.9-fold increase in mean Cmax and mean AUC of rosuvastatin respectively.</p></td><td><p>Due to an observed increased risk of myopathy/rhabdomyolysis, combination therapy with rosuvastatin and gemfibrozil should be avoided. If used together, the dose of rosuvastatin should not exceed 20 mg once daily.</p></td></tr><tr><td><p>Clopidogrel</p></td><td><p>Coadministration of rosuvastatin 20 mg (single dose) with clopidogrel 300 mg loading, followed by 75 mg at 24 hours resulted in approximately a 2-fold increase in the mean AUC of rosuvastatin.</p></td><td><p>The dose of rosuvastatin should not exceed 20 mg daily when used concomitantly with clopidogrel.</p></td></tr><tr><td><p>Eltrombopag</p></td><td><p>Coadministration of Rosuvastatin calcium 10 mg (single dose) and eltrombopag 75 mg (OD, 10 days) to healthy volunteers resulted in approximately a 1.6-fold increase in the mean AUC of rosuvastatin</p></td><td><p>The dose of rosuvastatin should not exceed 20 mg daily when used concomitantly with eltrombopag.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper </strong><strong>Name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical Comment</strong></p></td></tr><tr><td><p>Dronedarone</p></td><td><p>Coadministration of Rosuvastatin calcium and dronedarone 400 mg (bid) resulted in approximately a 1.4-fold increase in mean AUC of rosuvastatin.</p></td><td><p>The dose of rosuvastatin should not exceed 20 mg daily when used concomitantly with dronedarone.</p></td></tr><tr><td><p>Itraconazole</p></td><td><p>Coadministration of Rosuvastatin calcium 10 mg (single dose) with itraconazole 200 mg (OD, 5 days) to healthy volunteers resulted in a 1.4-fold increase in the mean AUC of rosuvastatin.</p></td><td><p>The dose of rosuvastatin should not exceed 20 mg daily when used concomitantly with itraconazole.</p></td></tr><tr><td><p>Coumarin Anticoagulants</p></td><td><p>As with other HMG-CoA reductase inhibitors, coadministration of rosuvastatin calcium and coumarin (e.g. warfarin) may result in a rise in International Normalized Ratio (INR) compared to coumarin alone. In healthy subjects, the coadministration of rosuvastatin 40 mg (10 days) and warfarin 25 mg (single dose) produced a higher mean maxINR and AUC-INR than achieved with warfarin alone. Coadministration of rosuvastatin calcium 10 and 80 mg to patients on stable warfarin therapy resulted in clinically significant rises in INR <strong>(</strong>&gt;4, baseline 2-3). The mechanism for this effect is unknown, but is likely due to a pharmacodynamic interaction with warfarin rather than a pharmacokinetic interaction as no relevant differences in the pharmacokinetics of either drug were observed.</p></td><td><p>In patients taking coumarin, monitoring of INR is recommended at initiation or cessation of therapy with rosuvastatin or following dose adjustment. Rosuvastatin therapy has not been associated with bleeding or changes in INR in patients not taking anticoagulants.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper </strong><strong>Name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical Comment</strong></p></td></tr><tr><td><p>Antacids</p></td><td><p>Simultaneous dosing of rosuvastatin calcium with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease of rosuvastatin plasma concentration by approximately 50%.</p></td><td><p>The clinical relevance of this interaction has not been studied. However, the effect was mitigated when the antacid was dosed 2 hours after rosuvastatin calcium. This interaction should not be clinically relevant in patients using this type of antacid infrequently. A frequent antacid user should be instructed to take rosuvastatin calcium at a time of day when they are less likely to need the antacid.</p></td></tr><tr><td><p>Fusidic Acid</p></td><td><p>Interaction studies with rosuvastatin and fusidic acid have not been conducted. As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with rosuvastatin and fusidic acid given concurrently.</p></td><td><p>Co-administration of rosuvastatin with fusidic acid should be avoided. Temporary suspension of rosuvastatin treatment may be appropriate when the use of fusidic acid is necessary.</p></td></tr><tr><td><p>Oral Contraceptives</p></td><td><p>When rosuvastatin calcium 40 mg was coadministered with a representative oral contraceptive (ethinyl estradiol [35 &mu;g] and norgestrel [180 &mu;g on days 1 to 7, 215 &mu;g on days 8 to 15, and 250 &mu;g on days 16 to 21]) no reduction in contraceptive efficacy was observed. An increase in plasma concentrations (AUC) of ethinyl estradiol (26%) and norgestrel (34%) occurred.</p></td><td><p>These increased plasma levels should be considered when selecting oral contraceptive doses.</p></td></tr></tbody></table><p>When it is necessary to coadminister APO-ROSUVASTATIN with other medicines known to increase exposure to rosuvastatin, start with a 5 mg once daily dose of APO-ROSUVASTATIN if the expected increase in exposure (AUC) is approximately 2 fold or higher.&nbsp; The maximum daily dose of APO-ROSUVASTATIN should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of APO-ROSUVASTATIN taken without interacting medicines (see 4.3 and 4.5, Drug-Drug Interactions (Table 3)).</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>APO-ROSUVASTATIN can be taken with or without food (see 4.2).</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u></strong></p><p><strong>Baicalin</strong>: Coadministration of baicalin (50 mg TID, 14 days) with rosuvastatin calcium (20 mg, single dose) resulted in a 47% decrease in the AUC of rosuvastatin.</p><p><strong>Silymarin (from milk thistle): &nbsp;</strong>Coadministration of silymarin (140 mg TID, 5 days) with Rosuvastatin calcium (10 mg, single dose) resulted in no change in plasma concentrations of rosuvastatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-ROSUVASTATIN should not be used during pregnancy or lactation (see 4.4, Special Populations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No known effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adverse Drug Reaction Overview</u></strong></p><p>Rosuvastatin calcium is generally well tolerated. The adverse events seen with rosuvastatin calcium are generally mild and transient.</p><p>Rosuvastatin calcium clinical trial experience is extensive, involving 9800 patients treated with rosuvastatin calcium in placebo controlled trials and 9855 patients treated with rosuvastatin calcium in active controlled clinical trials. Discontinuation of therapy due to adverse events occurred in 2.6% of patients receiving rosuvastatin calcium and 1.8% of patients receiving placebo. The most frequently reported adverse events at an incidence &ge; 1% and at a rate greater than placebo were arthralgia, upper abdominal pain and ALT increase. Adverse events observed or reported in short- and long-term trials are as follows.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p><em>Because</em><em> </em><em>clinical</em><em> trials are conducted under very specific conditions the adverse drug reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.</em></p><p><em>&nbsp;</em></p><p><strong>Adults</strong></p><p><u>Short-term Controlled Trials</u></p><p>Short-term controlled trials involved 1290 patients within placebo-controlled trials of 6 to 16 weeks&rsquo; duration (768 of which were treated with rosuvastatin) and 11641 patients within placebo and active controlled clinical trials of 6 to 52 weeks duration (5319 of which were treated with rosuvastatin). &nbsp;In all controlled clinical trials, 3.2% of patients were withdrawn from rosuvastatin calcium therapy due to adverse events. This withdrawal rate was comparable to that reported in placebo-controlled studies.</p><p>Associated adverse events occurring at an incidence &ge; 1% in patients participating in placebo- controlled clinical studies of rosuvastatin, are shown in Table 1.</p><p>&nbsp;</p><p><strong>Table 1 Number (%) of Subjects with Associated Adverse Events Occurring with&nbsp;&ge;1% Incidence in any Treatment Group: Placebo Controlled Pool</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System/ Adverse Event</strong></p></td><td><p><strong>Placebo</strong><strong> (%) (N=367)</strong></p></td><td><p><strong>Total rosuvastatin (%) (N=768)</strong></p></td></tr><tr><td><p><strong>Whole Body</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>2.2</p></td><td><p>1.7</p></td></tr><tr><td><p>Asthenia</p></td><td><p>0.5</p></td><td><p>1.3</p></td></tr><tr><td><p>Headache</p></td><td><p>2.2</p></td><td><p>1.4</p></td></tr><tr><td><p><strong>Digestive</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Constipation</p></td><td><p>1.4</p></td><td><p>1.0</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>1.6</p></td><td><p>1.3</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>1.9</p></td><td><p>0.7</p></td></tr><tr><td><p>Flatulence</p></td><td><p>2.7</p></td><td><p>1.8</p></td></tr><tr><td><p>Nausea</p></td><td><p>1.6</p></td><td><p>2.2</p></td></tr><tr><td><p><strong>Musculoskeletal</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Myalgia</p></td><td><p>0.5</p></td><td><p>1.6</p></td></tr><tr><td><p><strong>Nervous</strong><strong> System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dizziness</p></td><td><p>1.6</p></td><td><p>0.5</p></td></tr><tr><td><p>Insomnia</p></td><td><p>1.9</p></td><td><p>0.4</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Long-term Controlled Morbidity and Mortality Trials</u></p><p>In the <strong>J</strong>ustification for the <strong>U</strong>se of Statins in <strong>P</strong>rimary Prevention: An <strong>I</strong>ntervention <strong>T</strong>rial <strong>E</strong>valuating <strong>R</strong>osuvastatin (JUPITER) study involving 17,802 participants treated with rosuvastatin calcium 20 mg once daily (n=8901) or placebo (n=8901), rosuvastatin calcium 20 mg was generally well tolerated. Subjects were followed for a mean duration of 2 years.</p><p>Discontinuation of therapy due to an adverse event occurred in 5.6% of subjects treated with rosuvastatin calcium and 5.5% of subjects treated with placebo. The most common adverse events that led to discontinuation from the study were: myalgia, arthralgia, abdominal pain and constipation. The associated adverse reaction reported in &ge; 1% of patients and at a rate greater than or equal to placebo was myalgia (2.4% rosuvastatin calcium, 2.0% placebo.)</p><p>Treatment emergent adverse events regardless of causality occurring at an incidence &ge; 1% and at a rate greater than placebo in patients participating in the JUPITER trial are shown in Table 2.</p><p>&nbsp;</p><p><strong>Table 2 Number (%) of Subjects with Treatment Emergent Adverse Events Regardless of Causality Occurring with &ge; 1% Incidence and &gt; than Placebo: JUPITER</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System/Adverse Event</strong></p></td><td><p><strong>Placebo</strong><strong> (%) (N=8901)</strong></p></td><td><p><strong>Total</strong><strong> Rosuvastatin 20 mg (%) (N = 8901)</strong></p></td></tr><tr><td><p><strong>Blood</strong></p><p>Anemia</p></td><td><p><strong>&nbsp;</strong></p><p>2.1</p></td><td><p><strong>&nbsp;</strong></p><p>2.2</p></td></tr><tr><td><p><strong>Cardiac</strong></p><p>Palpitations</p></td><td><p><strong>&nbsp;</strong></p><p>0.9</p></td><td><p><strong>&nbsp;</strong></p><p>1.0</p></td></tr><tr><td><p><strong>Gastrointestinal</strong></p><p>Diarrhea</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>4.6</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>4.7</p></td></tr><tr><td><p>Constipation</p></td><td><p>3.0</p></td><td><p>3.3</p></td></tr><tr><td><p>Nausea</p></td><td><p>2.3</p></td><td><p>2.4</p></td></tr><tr><td><p><strong>General</strong><strong> disorders</strong></p><p>Edema peripheral</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>3.0</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>3.7</p></td></tr><tr><td><p>Fatigue</p></td><td><p>3.5</p></td><td><p>3.7</p></td></tr><tr><td><p><strong>Hepatobiliary</strong></p><p>Cholelithiasis</p></td><td><p><strong>&nbsp;</strong></p><p>0.9</p></td><td><p><strong>&nbsp;</strong></p><p>1.0</p></td></tr><tr><td><p><strong>Infections</strong></p><p>Urinary tract</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>8.6</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>8.7</p></td></tr><tr><td><p>Nasopharyngitis</p></td><td><p>7.2</p></td><td><p>7.6</p></td></tr><tr><td><p>Bronchitis</p></td><td><p>7.1</p></td><td><p>7.2</p></td></tr><tr><td><p>Sinusitis</p></td><td><p>3.7</p></td><td><p>4.0</p></td></tr><tr><td><p>Influenza</p></td><td><p>3.6</p></td><td><p>4.0</p></td></tr><tr><td><p>Lower Respiratory tract</p></td><td><p>2.7</p></td><td><p>2.9</p></td></tr><tr><td><p>Gastroenteritis</p></td><td><p>1.7</p></td><td><p>1.9</p></td></tr><tr><td><p>Herpes zoster</p></td><td rowspan="1"><p>1.4</p></td><td rowspan="1"><p>1.6</p></td></tr><tr><td><p><strong>Injury</strong></p><p>Contusion</p></td><td><p><strong>&nbsp;</strong></p><p>1.4</p></td><td><p><strong>&nbsp;</strong></p><p>1.7</p></td></tr><tr><td><p><strong>Investigation</strong></p><p>ALT increased</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>1.0</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>1.4</p></td></tr><tr><td><p>Blood glucose increased</p></td><td rowspan="1"><p>0.7</p></td><td rowspan="1"><p>1.0</p></td></tr><tr><td><p><strong>Metabolism</strong></p><p>Diabetes mellitus</p></td><td><p><strong>&nbsp;</strong></p><p>2.5</p></td><td><p><strong>&nbsp;</strong></p><p>3.0</p></td></tr><tr><td><p><strong>Musculoskeletal</strong></p><p>Back pain</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>6.9</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>7.6</p></td></tr><tr><td><p>Myalgia</p></td><td><p>6.6</p></td><td><p>7.6</p></td></tr><tr><td><p>Arthritis</p></td><td><p>5.6</p></td><td><p>5.8</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>3.2</p></td><td><p>3.8</p></td></tr><tr><td><p>Muscle spasms</p></td><td><p>3.2</p></td><td><p>3.6</p></td></tr><tr><td><p>Osteoarthritis</p></td><td><p>1.4</p></td><td><p>1.8</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System/ Adverse Event</strong></p></td><td><p><strong>Placebo</strong><strong> (%) (N=8901)</strong></p></td><td><p><strong>Total</strong><strong> Rosuvastatin 20 mg (%) (N = 8901)</strong></p></td></tr><tr><td><p>Bursitis</p></td><td><p>1.3</p></td><td><p>1.5</p></td></tr><tr><td><p>Neck Pain</p></td><td><p>1.0</p></td><td><p>1.1</p></td></tr><tr><td><p>Osteoporosis</p></td><td><p>0.8</p></td><td><p>1.0</p></td></tr><tr><td><p><strong>Neoplasms</strong></p><p>Basal cell carcinoma</p></td><td><p><strong>&nbsp;</strong></p><p>0.9</p></td><td><p><strong>&nbsp;</strong></p><p>1.0</p></td></tr><tr><td><p><strong>Psychiatric</strong></p><p>Insomnia</p></td><td><p><strong>&nbsp;</strong></p><p>2.3</p></td><td><p><strong>&nbsp;</strong></p><p>2.5</p></td></tr><tr><td><p><strong>Renal</strong></p><p>Hematuria</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>2.0</p></td><td rowspan="1"><p><strong>&nbsp;</strong></p><p>2.4</p></td></tr><tr><td><p>Proteinuria</p></td><td><p>1.3</p></td><td><p>1.4</p></td></tr><tr><td><p><strong>Respiratory</strong></p><p>Epistaxis</p></td><td><p><strong>&nbsp;</strong></p><p>0.8</p></td><td><p><strong>&nbsp;</strong></p><p>1.0</p></td></tr></tbody></table><p><strong><u>Less</u></strong><strong><u> Common Clinical Trial Adverse Drug Reactions (&lt; 1%</u></strong><strong>)</strong></p><p>The frequency of adverse events in all clinical trials and considered possibly, probably or definitely drug related are as follows:</p><p>&nbsp;</p><p><strong>Uncommon (&ge; 0.1% and &lt; 1%)</strong>: Pruritus, rash, urticaria, arthralgia, muscle weakness, arthritis, constipation, nausea, dyspepsia, gastroesophageal reflux disease, ALT increase, creatine phosphokinase increase, hepatic enzyme increase, creatinine increase, paraesthesia, tremor, general pain, proteinuria, sinusitis, insomnia, abnormal hepatic function, vertigo, diabetes mellitus.</p><p><strong>Rare (&ge; 0.01% and &lt; 0.1%):</strong> Myopathy (including myositis), rhabdomyolysis and hypersensitivity reactions including angioedema.</p><p>&nbsp;</p><p>The following additional adverse events were reported in controlled clinical trials, regardless of causality:</p><p>Accidental injury, back and chest pain, flu syndrome, infection, urinary tract infection, diarrhea, flatulence, gastroenteritis, hypertonia, bronchitis, increased cough, rhinitis and pharyngitis.</p><p>&nbsp;</p><p>In long-term controlled clinical trials rosuvastatin calcium was shown to have no harmful effect on the ocular lens.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p>As with other HMG-CoA reductase inhibitors, a dose-related increase in liver transaminases and CK has been observed in a small number of patients taking rosuvastatin (see 4.4, Hepatic/Biliary/Pancreatic).</p><p>Abnormal urinalysis testing (dipstick-positive proteinuria) has been seen in a small number of patients taking rosuvastatin calcium and other HMG-CoA reductase inhibitors. The protein&nbsp;detected was mostly tubular in origin. In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and is not predictive of acute or progressive renal disease (see 4.4, Renal).</p><p>In the JUPITER trial, occurrences of diabetes mellitus as a pre-specified secondary outcome were reported more frequently in the rosuvastatin calcium-treated patients (2.8%) than in placebo (2.3%) and a slight increase in the number of subjects whose fasting glucose levels increased to &ge; 7.0 mmol/L (126mg/dL) was observed in subjects treated with rosuvastatin calcium who were primarily already at high risk for developing diabetes. There was a 0.1% increase in mean HbA1c with rosuvastatin calcium compared to placebo. A causal relationship with statins and diabetes mellitus has not been definitely established.</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>Because post-market reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. &nbsp;In addition to the events reported above, the following adverse events have been reported during post-marketing experience with rosuvastatin calcium, regardless of causality assessment.</p><p>&nbsp;</p><p><strong>Skeletal muscle effects: </strong>Very rare: arthralgia, immune-mediated necrotizing myopathy</p><p>It has been observed that as with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis in post-marketing use is higher at the highest marketed dose (see 4.4, Muscle Effects).</p><p><strong>Hematological disorders:</strong> Thrombocytopenia has been reported with rosuvastatin calcium.</p><p><strong>Hepatobiliary disorders:&nbsp;</strong>Very rare: jaundice, hepatitis</p><p><strong>Nervous system disorders:</strong></p><p>Very rare: memory loss;</p><p>frequency unknown: peripheral neuropathy</p><p><strong>Endocrine disorders:</strong> Increases in fasting glucose and HbA1c levels have been reported with Rosuvastatin calcium</p><p><strong>Other: </strong></p><p>Rare: pancreatitis;</p><p>Very rare: gynecomastia</p><p>The following adverse events have been reported with some statins: Sleep Disturbances, including insomnia and nightmares.</p><p>Mood related disorders including depression. Fatal and non-fatal hepatic failure.</p><p>Cases of erectile dysfunction have been reported in association with the use of statins.</p><p>Interstitial lung disease: very rare cases of interstitial lung disease, especially with long term therapy. If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>There have been rare post-marketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins.&nbsp; The reports are generally non-serious and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p><p>&nbsp;</p><p>To report any side effects:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdosage. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of rosuvastatin.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Mechanism of Action</u></strong></p><p>APO-ROSUVASTATIN (rosuvastatin calcium) is a synthetic, enantiomerically pure lipid- lowering agent. It is a selective, potent and competitive inhibitor of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase. This enzyme catalyses the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in cholesterol biosynthesis.</p><p>Studies have shown that rosuvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver by increasing the number of hepatic Low Density Lipoprotein (LDL) receptors on the cell-surface for enhanced uptake and catabolism of LDL. Additionally, rosuvastatin calcium inhibits the hepatic synthesis of Very Low Density Lipoprotein (VLDL), thereby reducing the total number of VLDL and LDL particles.</p><p>&nbsp;</p><p><strong><u>Pharmacodynamics</u></strong></p><p>Epidemiologic, clinical and experimental studies have established that high LDL-C, low HDL-C and high plasma TG promote human atherosclerosis and are risk factors for developing cardiovascular disease. Some studies have also shown that the total-C/HDL-C ratio is the best predictor of coronary artery disease. In contrast, increased levels of HDL-C are associated with decreased cardiovascular risk. Drug therapies that reduce levels of LDL-C or decrease TG while simultaneously increasing HDL-C have demonstrated reductions in rates of cardiovascular mortality and morbidity.</p><p><strong>See </strong><strong>also 5.4 -&nbsp;</strong>Human Pharmacology.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong></p><p>APO-ROSUVASTATIN is administered orally following which rosuvastatin, the active moiety, is rapidly absorbed, reaching peak plasma concentration 3 to 5 hours after dosing.</p><p>Both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increase in proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20% and there is no accumulation on repeated dosing.&nbsp; Rosuvastatin calcium may be given with or without food. Administration in the morning or evening did not affect the rate and extent of absorption nor the ability of rosuvastatin to reduce LDL-C.</p><p>&nbsp;</p><p><strong>Distribution:</strong></p><p>Rosuvastatin undergoes first pass extraction in the liver, which is the primary site of cholesterol synthesis and LDL-C clearance. The mean volume of distribution at steady state of rosuvastatin is approximately 134 litres. Rosuvastatin is approximately 90% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.</p><p>&nbsp;</p><p><strong>Metabolism:</strong></p><p>Rosuvastatin is not extensively metabolised with approximately 10% of a radiolabeled dose recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in <em>in vitro </em>studies has demonstrated to have approximately one-half the HMG-CoA reductase inhibitory activity of rosuvastatin. The parent compound accounts for greater than 87% of the circulating active HMG-CoA reductase inhibitor activity.</p><p>&nbsp;</p><p><strong>Excretion:</strong></p><p>Following an oral dose, rosuvastatin and its metabolites are primarily excreted in the faeces (90%) with the remainder being excreted in the urine. Fecal recovery represents absorbed drug, metabolites in the bile, and unabsorbed drug. The elimination half-life (t&frac12;) of rosuvastatin is approximately 19 hours and does not increase with increasing doses.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions:</u></strong></p><p><strong>Race</strong>:</p><p>A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic and Black or Afro-Caribbean groups.</p><p>However, pharmacokinetic studies with rosuvastatin, including one conducted in North America, have demonstrated an approximate 2-fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with a Caucasian control group (see 4.3 and 4.4, Special Populations, Race and 4.2, Race).</p><p>&nbsp;</p><p><strong>Genetic polymorphisms:</strong></p><p>Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. &nbsp;In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. &nbsp;Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with an approximate 1.7-fold higher rosuvastatin exposure (AUC) or 2.4-fold higher exposure, respectively, compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes.</p><p>&nbsp;</p><p><strong>Primary dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)</strong></p><p>In a randomized, multicenter, double-blind crossover study, 32 patients (27 with &epsilon;2/&epsilon;2 genotype and 4 with apo E mutation [Arg145Cys]) with dysbetalipoproteinemia (Fredrickson type III) received rosuvastatin calcium 10 or 20 mg daily for 6 weeks. Rosuvastatin calcium 10 and 20 mg reduced non-HDL-C (primary end point) by 48% (95% CI: 45.6, 56.7) and 56% (95% CI: 48.5, 61.4), respectively. Rosuvastatin calcium 10 and 20 mg respectively, also reduced Total-C (43% and 48%), TG (40% and 43%), VLDL-C + IDL-C (47% and 56%), LDL-C (54% and 57%), Remnant Lipoprotein Cholesterol (56% and 65%), Apo E (43% and 43%) and increased HDL-C (10% and 11%). The effect of rosuvastatin calcium on morbidity and mortality in this patient population has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute</strong><strong> </strong><strong>Toxicity</strong></p><p>Rosuvastatin was shown to be of low acute toxicity following administration of single doses to rats and dogs by oral and intravenous routes. There were no mortalities in rats given an oral dose of 1000 mg/kg or 2000 mg/kg, and other than depression of bodyweight at 2000 mg/kg, there were no treatment-related effects at either dose level. Dogs received oral doses of 1000 mg/kg or 2000 mg/kg with vomiting on the day of dosing observed as the major clinical finding in both sexes. Biochemical changes (increased plasma enzymes, decreased lipids) and hematological change (increased white blood cells) were found in dogs given an oral dose of up to and including 2000 mg/kg. Lethality was observed immediately after dosing in 1/1 of rats given an intravenous dose of 500 mg/kg but two rats given 250 mg/kg intravenously showed slight hypopnea and weakness soon after dosing with no subsequent effects. The results are summarized below:</p><p>&nbsp;</p><p><strong>Table 7 Acute Oral and Intravenous Toxicity Studies with Rosuvastatin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p><p><strong>Species</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Route</strong></p></td><td><p><strong>Dose Levels for One or Both Sexes (mg/kg)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Mortalities</strong></p></td></tr><tr><td><p>Rat</p></td><td><p>Oral</p></td><td><p>1000 and 2000</p></td><td><p>0/1 at 1000 mg/kg; 0/2 at 2000 mg/kg</p></td></tr><tr><td><p>Rat</p></td><td><p>Intravenous</p></td><td><p>250 and 500</p></td><td><p>1/1 died at 500 mg/kg; 0/2 at 250 mg/kg</p></td></tr><tr><td><p>Rat</p></td><td><p>Oral</p></td><td><p>1000 and 2000</p></td><td><p>0/12 at 1000 mg/kg; 0/12 at 2000 mg/kg</p></td></tr><tr><td><p>Dog</p></td><td><p>Oral</p></td><td><p>1000 and 2000</p></td><td><p>0/2 at 1000 mg/kg; 0/2 at 2000 mg/kg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Subacute</strong><strong> </strong><strong>and Chronic Toxicity</strong></p><p>The significant target organs affected by rosuvastatin in multiple dose toxicity studies in rats (14 days to 6 months), mice (2 weeks to 13 weeks), Cynomolgus monkeys (30 days to 6 months), dogs (14 days to 12 months) and rabbits (developmental toxicity study) are summarized in Table 8 below.</p><p>&nbsp;</p><p><strong>Table 8 Rosuvastatin: Target Organs Affected in Animal Studies</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Mouse</strong></p></td><td><p><strong>Rat</strong></p></td><td><p><strong>Cynomolgus</strong><strong> Monkey</strong></p></td><td><p><strong>Dog</strong></p></td><td><p><strong>Rabbit</strong></p></td></tr><tr><td><p>Liver - increased weight and centrilobular hypertrophy</p></td><td><p>Liver - increased weight, eosinophilia, periportal necrosis and intralobular bile duct hypertrophy, increased liver-related plasma enzymes</p></td><td><p>Testis - reduced spermatogenic epithelium with vacuolation</p></td><td><p>Liver &mdash; increased liver- related plasma enzymes</p></td><td><p>Skeletal Muscle - focal degeneration and necrosis of perivascular myocardium and other skeletal muscle tissue</p></td></tr><tr><td><p>Stomach (non- glandular)** - hyperplasia of squamous epithelium and hyperkeratosis of forestomach mucosa</p></td><td><p>Stomach (non- glandular)** - hyperplasia of squamous epithelium and hyperkeratosis of forestomach mucosa</p></td><td><p>Kidney - cortical tubular epithelial cell necrosis with regeneration</p></td><td><p>Gallbladder - hemorrhage, edema and/or inflammatory cell infiltrate in lamina propria mucosa</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gall bladder* - hemorrhage, edema and/or inflammatory cell infiltration in lamina propria mucosa</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Lens*** - punctate or striate opacities in anterior portion of the lens</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Brain* - edema, hemorrhage and partial necrosis in choroid plexus</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Testis - tubular degeneration and atrophy</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* Occurred after administration of high, intolerable doses (250 mg/kg/day [mouse gall bladder], 90 mg kg/day [dog brain])</p><p>** Unique anatomical structure not relevant to human</p><p>*** Not a consequence of prolonged dosing</p><p>&nbsp;</p><p>Table 9 summarizes the significant adverse changes observed during chronic toxicology studies in the mouse (104 weeks), rat (6 months), dog (12 months), Cynomolgus monkey (6 months) and rabbit (developmental toxicity study).</p><p>Table 9: Rosuvastatin: Significant Adverse Changes in Subacute and Chronic Studies</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>Margin</strong><strong> </strong><strong>vs. NOAEL: 40 mg</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Species/Finding</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>No-Effect</strong><strong> </strong><strong>Dose (mg/kg/day)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Minimal</strong><strong> Toxic Dose (mg/kg/day)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Cmax</strong><strong> (adjusted for protein binding (ng/mL)</strong></p></td><td><p><strong>AUC</strong><strong> (adjusted for protein binding) (ng∙h/mL)</strong></p></td></tr><tr><td><p><strong>Mouse</strong></p><p>Liver carcinoma</p></td><td><p><strong>&nbsp;</strong></p><p>60</p></td><td><p><strong>&nbsp;</strong></p><p>200</p></td><td><p><strong>&nbsp;</strong></p><p>19</p></td><td><p><strong>&nbsp;</strong></p><p>4.9</p></td></tr><tr><td><p><strong>Rat </strong></p><p>Forestomach hyperkeratosis</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&gt; 20</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&gt; 20</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>12</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Plasma liver enzymes</p></td><td><p><strong>&nbsp;</strong></p><p>&gt; 20</p></td><td><p><strong>&nbsp;</strong></p><p>&gt; 20</p></td><td><p><strong>&nbsp;</strong></p><p>12</p></td><td><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Hepatocellular necrosis</p></td><td><p><strong>&nbsp;</strong></p><p>2</p></td><td><p><strong>&nbsp;</strong></p><p>6</p></td><td><p><strong>&nbsp;</strong></p><p>0.44</p></td><td><p><strong>&nbsp;</strong></p><p>0.3</p></td></tr><tr><td><p>Muscle necrosis</p></td><td><p>80</p><p>(2 yr study)</p></td><td><p>80</p><p>(13 wk study)</p></td><td><p><strong>&nbsp;</strong></p><p>26</p></td><td><p><strong>&nbsp;</strong></p><p>6.5</p></td></tr><tr><td><p>Uterine polyps</p></td><td><p>60</p></td><td><p>80</p></td><td><p>23</p></td><td><p>5</p></td></tr><tr><td><p><strong>Dog</strong></p><p>Plasma liver enzymes</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>3</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>3.9</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Hepatocellular atrophy</p></td><td><p><strong>&nbsp;</strong></p><p>3</p></td><td><p><strong>&nbsp;</strong></p><p>6</p></td><td><p><strong>&nbsp;</strong></p><p>3.9</p></td><td><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Gall bladder edema and hemorrhage</p></td><td><p><strong>&nbsp;</strong></p><p>3</p></td><td><p><strong>&nbsp;</strong></p><p>6</p></td><td><p><strong>&nbsp;</strong></p><p>3.9</p></td><td><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Ocular opacity</p></td><td><p>15</p></td><td><p>30</p></td><td><p>19</p></td><td><p>2.4</p></td></tr><tr><td><p>Testicular tubular degeneration</p></td><td><p><strong>&nbsp;</strong></p><p>30</p></td><td><p><strong>&nbsp;</strong></p><p>90</p></td><td><p><strong>&nbsp;</strong></p><p>33</p></td><td><p><strong>&nbsp;</strong></p><p>20</p></td></tr><tr><td><p><strong>Monkey</strong><strong> </strong></p><p>Testicular tubular degeneration</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>10</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>30</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>2.3</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p>Renal tubular necrosis</p></td><td><p><strong>&nbsp;</strong></p><p>10</p></td><td><p><strong>&nbsp;</strong></p><p>30</p></td><td><p><strong>&nbsp;</strong></p><p>2.3</p></td><td><p><strong>&nbsp;</strong></p><p>4</p></td></tr><tr><td><p><strong>Rabbit</strong></p><p>Muscle necrosis</p></td><td><p><strong>&nbsp;</strong></p><p>1*</p></td><td><p><strong>&nbsp;</strong></p><p>3*</p></td><td><p><strong>&nbsp;</strong></p><p>0.2**</p></td><td><p><strong>&nbsp;</strong></p><p>Not available</p></td></tr></tbody></table><p>* rabbit teratology study&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ** exposure determined in a separate toxicokinetic study</p><p>&nbsp;</p><p>The toxicology profile of rosuvastatin appears similar to that observed with other statins and is a consequence of its primary pharmacology action (i.e. inhibition of the enzyme, HMG-CoA reductase) which leads to reduced cholesterol synthesis.</p><p>&nbsp;</p><p><strong>Carcinogenicity/Mutagenicity</strong></p><p>In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60 or 80 mg/kg/day, the incidence of uterine polyps was statistically significantly increased only in females at the dose of 80 mg/kg/day. This dose produced a plasma AUC (0-24)&nbsp;value approximately 8 times higher (after correction for interspecies differences in protein binding) than the human plasma drug exposure after a 40 mg dose at steady state. Increased incidences of polyps observed at 2, 20 and 60 mg/kg/day were not statistically different from the control group not exposed to rosuvastatin.</p><p>The 60 mg/kg/day dose produced a plasma AUC (0-24) value approximately <em>5 </em>times higher (after correction for interspecies differences in protein binding) than the mean human exposure after a 40 mg dose at steady state. The occurrence of uterine polyps in old female rats is well-known and is considered benign tumors and lesions termed non-neoplastic in humans.</p><p>In a 107-week carcinogenicity study in mice given 10, 60, 200 or 400 mg/kg/day, the 400 mg/kg/day dose was poorly tolerated, resulting in early termination of this dose group. An increased incidence of hepatocellular carcinomas was observed at 200 mg/kg/day and an increase in hepatocellular adenomas was seen at 60 and 200 mg/kg/day. The dose of 200 mg/kg/day produced a plasma AUC (0-24)&nbsp;value approximately 37 times higher (after correction for interspecies differences in protein binding) than the mean human plasma drug exposure after a 40 mg dose at steady state. An increased incidence of hepatocellular tumors was not seen at 10 mg/kg/day. The 60 mg/kg/day dose produced a plasma AUC(0-24) value approximately 4.9 times higher (after correction for interspecies differences in protein binding) than the mean human plasma drug exposure after a 40 mg dose at steady state. These hepatocellular effects are known to occur in rodents treated with statins without evidence of similar effects in humans.</p><p><em>In vitro, </em>rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with <em>Salmonella</em><em> typhimurium </em>and <em>Escherichia</em><em> coli</em>, L-5178 y &plusmn; mouse lymphomas, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the <em>in vivo </em>mouse micronucleus test.</p><p>&nbsp;</p><p><strong>Teratology and Reproductive Studies</strong></p><p>The reproductive toxicity of rosuvastatin has been evaluated in fertility and pre- and post-natal developmental studies, at doses up to 50 mg/kg/day. Slight reductions in maternal body weight gain and food consumption were observed at 50 mg/kg/day. Rosuvastatin had no adverse effects on mating, fertility in both sexes, implantation and maintenance of pregnancy, pup morphology or survival at 50 mg/kg/day in the fertility study. In a pre- and post-natal sighting study in rats given &ge; 75 mg/kg/day there was reduced pup survival at birth at 125 and 150 mg/kg/day and during early lactation at 75 and 100 mg/kg/day. In the main pre- and post-natal developmental study, rosuvastatin showed no adverse effects on the duration of pregnancy, delivery and lactation in the dams in either generation at the high dose of 50 mg/kg/day. In the absence of plasma AUC exposure data in pregnant rats, comparisons with human data have been made on a received dose basis. The dose of 50 mg/kg/day equates to 90 times the human dose of 40 mg given to a 70 kg human.</p><p>The potential of rosuvastatin to cause developmental toxicity has been examined in the pregnant rat at doses up to 100 mg/kg/day and in the pregnant rabbit at doses up to 3 mg/kg/day.</p><p>Rosuvastatin was shown to be neither embryo-fetolethal nor teratogenic in rats. At a maternally toxic dose of 3 mg/kg/day in rabbits, fetal examination showed no evidence of fetolethality or teratogenicity.</p><p>Overall, rosuvastatin has shown no reproductive or developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;Table 1: Tablet composition of Apo-Rosuvastatin Tablets 5 mg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Component and Quality Standard (and Grade, if applicable)</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Function of Component</strong></p></td><td colspan="2"><p><strong>Quantity</strong></p></td></tr><tr><td><p><strong>mg/tablet</strong></p></td><td><p><strong>% w/w</strong></p></td></tr><tr><td colspan="4"><p><strong>CORE</strong></p></td></tr><tr><td><p>Rosuvastatin Calcium<sup>$</sup></p></td><td><p>Active</p></td><td><p>5.3</p></td><td><p>5.3</p></td></tr><tr><td><p>Lactose Monohydrate NF (Spray-Dried)<sup>$</sup></p></td><td><p>Diluent</p></td><td><p>68.6</p></td><td><p>68.6</p></td></tr><tr><td><p>Microcrystalline Cellulose NF (PH 102)</p></td><td><p>Diluent/ Binder</p></td><td><p>16.4</p></td><td><p>16.4</p></td></tr><tr><td><p>Crospovidone NF</p></td><td><p>Disintegrant</p></td><td><p>8.0</p></td><td><p>8.0</p></td></tr><tr><td><p>Magnesium Stearate NF</p></td><td><p>Lubricant</p></td><td><p>1.5</p></td><td><p>1.5</p></td></tr><tr><td><p>Colloidal Silicon Dioxide NF</p></td><td><p>Glidant</p></td><td><p>0.2</p></td><td><p>0.2</p></td></tr><tr><td colspan="2"><p><strong>Total Core</strong></p></td><td><p><strong>100</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="4"><p><strong>COATING</strong></p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 USP E5</p></td><td><p>Film Forming Polymer</p></td><td><p>0.900</p></td><td><p>30.00</p></td></tr><tr><td><p>Hydroxypropyl Cellulose NF Type LF</p></td><td><p>Film Forming Polymer</p></td><td><p>0.300</p></td><td><p>10.00</p></td></tr><tr><td><p>Polyethylene Glycol 8000 NF</p></td><td><p>Plasticizer</p></td><td><p>0.600</p></td><td><p>20.00</p></td></tr><tr><td><p>Titanium Dioxide USP</p></td><td><p>Opacifier</p></td><td><p>1.005</p></td><td><p>33.50</p></td></tr><tr><td><p>Yellow Ferric Oxide NF</p></td><td><p>Colourant</p></td><td><p>0.195</p></td><td><p>6.50</p></td></tr><tr><td><p>Purified Water USP*</p></td><td><p>Solvent</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td colspan="2"><p><strong>Total Coating Solution (excluding water):</strong></p></td><td><p><strong>3.0</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="2"><p><strong>TOTAL TABLET WEIGHT (excluding water):</strong></p></td><td><p><strong>103.0</strong></p></td><td><p><strong>--</strong></p></td></tr></tbody></table><p><sup>$</sup>Amount based on theoretical 100% potency of rosuvastatin calcium drug substance on the dried basis and typical water content (~1.8%). Actual quantity of rosuvastatin calcium is to be adjusted based on as is assay for Rosuvastatin. Lactose Monohydrate to be used for weight adjustment.</p><p>* Evaporated during coating process.</p><p>&nbsp;</p><p><strong>Table 2: Tablet composition of Apo-Rosuvastatin Tablets 10 mg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Component and Quality Standard (and Grade, if applicable)</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Function of Component</strong></p></td><td colspan="2"><p><strong>Quantity</strong></p></td></tr><tr><td><p><strong>mg/tablet</strong></p></td><td><p><strong>% w/w</strong></p></td></tr><tr><td colspan="4"><p><strong>CORE</strong></p></td></tr><tr><td><p>Rosuvastatin Calcium<sup>$</sup></p></td><td><p>Active</p></td><td><p>10.6</p></td><td><p>7.067</p></td></tr><tr><td><p>Lactose Monohydrate NF (Spray-Dried)<sup>$</sup></p></td><td><p>Diluent</p></td><td><p>100.25</p></td><td><p>66.83</p></td></tr><tr><td><p>Microcrystalline Cellulose NF (PH 102)</p></td><td><p>Diluent/ Binder</p></td><td><p>24.6</p></td><td><p>16.4</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Crospovidone NF</p></td><td><p>Disintegrant</p></td><td><p>12.0</p></td><td><p>8.0</p></td></tr><tr><td><p>Magnesium Stearate NF</p></td><td><p>Lubricant</p></td><td><p>2.25</p></td><td><p>1.5</p></td></tr><tr><td><p>Colloidal Silicon Dioxide NF</p></td><td><p>Glidant</p></td><td><p>0.3</p></td><td><p>0.2</p></td></tr><tr><td colspan="2"><p><strong>Total Core</strong></p></td><td><p><strong>150</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="4"><p><strong>COATING</strong></p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 USP E5</p></td><td><p>Film Forming Polymer</p></td><td><p>1.35</p></td><td><p>30.00</p></td></tr><tr><td><p>Hydroxypropyl Cellulose NF Type LF</p></td><td><p>Film Forming Polymer</p></td><td><p>0.450</p></td><td><p>10.00</p></td></tr><tr><td><p>Polyethylene Glycol 8000 NF</p></td><td><p>Plasticizer</p></td><td><p>0.900</p></td><td><p>20.00</p></td></tr><tr><td><p>Titanium Dioxide USP</p></td><td><p>Opacifier</p></td><td><p>1.764</p></td><td><p>39.20</p></td></tr><tr><td><p>Red Ferric Oxide NF - Orange Shade</p></td><td><p>Colourant</p></td><td><p>0.036</p></td><td><p>0.8</p></td></tr><tr><td><p>Purified Water USP*</p></td><td><p>Solvent</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td colspan="2"><p><strong>Total Coating Solution (excluding water):</strong></p></td><td><p><strong>4.5</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="2"><p><strong>TOTAL TABLET WEIGHT (excluding water):</strong></p></td><td><p><strong>154.5</strong></p></td><td><p><strong>--</strong></p></td></tr></tbody></table><p><sup>$</sup>Amount based on theoretical 100% potency of rosuvastatin calcium drug substance on the dried basis and typical water content (~1.8%). Actual quantity of rosuvastatin calcium is to be adjusted based on as is assay for Rosuvastatin. Lactose Monohydrate to be used for weight</p><p>adjustment.</p><p>* Evaporated during coating process.</p><p>&nbsp;</p><p><strong>Table 3: Tablet composition of Apo-Rosuvastatin Tablets 20 mg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p><p><strong>Component and Quality Standard (and Grade, if applicable)</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Function of Component</strong></p></td><td colspan="2"><p><strong>Quantity</strong></p></td></tr><tr><td><p><strong>mg/tablet</strong></p></td><td><p><strong>% w/w</strong></p></td></tr><tr><td colspan="4"><p><strong>CORE</strong></p></td></tr><tr><td><p>Rosuvastatin Calcium<sup>$</sup></p></td><td><p>Active</p></td><td><p>21.2</p></td><td><p>7.067</p></td></tr><tr><td><p>Lactose Monohydrate NF (Spray-Dried)<sup>$</sup></p></td><td><p>Diluent</p></td><td><p>200.5</p></td><td><p>66.83</p></td></tr><tr><td><p>Microcrystalline Cellulose NF (PH 102)</p></td><td><p>Diluent/ Binder</p></td><td><p>49.2</p></td><td><p>16.4</p></td></tr><tr><td><p>Crospovidone NF</p></td><td><p>Disintegrant</p></td><td><p>24</p></td><td><p>8.0</p></td></tr><tr><td><p>Magnesium Stearate NF</p></td><td><p>Lubricant</p></td><td><p>4.5</p></td><td><p>1.5</p></td></tr><tr><td><p>Colloidal Silicon Dioxide NF</p></td><td><p>Glidant</p></td><td><p>0.6</p></td><td><p>0.2</p></td></tr><tr><td colspan="2"><p><strong>Total Core</strong></p></td><td><p><strong>300</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="4"><p><strong>COATING</strong></p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 USP E5</p></td><td><p>Film Forming Polymer</p></td><td><p>2.70</p></td><td><p>30.00</p></td></tr><tr><td><p>Hydroxypropyl Cellulose NF Type LF</p></td><td><p>Film Forming Polymer</p></td><td><p>0.900</p></td><td><p>10.00</p></td></tr><tr><td><p>Polyethylene Glycol 8000 NF</p></td><td><p>Plasticizer</p></td><td><p>1.800</p></td><td><p>20.00</p></td></tr><tr><td><p>Titanium Dioxide USP</p></td><td><p>Opacifier</p></td><td><p>3.528</p></td><td><p>39.20</p></td></tr><tr><td><p>Red Ferric Oxide NF - Orange Shade</p></td><td><p>Colourant</p></td><td><p>0.072</p></td><td><p>0.8</p></td></tr><tr><td><p>Purified Water USP*</p></td><td><p>Solvent</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td colspan="2"><p><strong>Total Coating Solution (excluding water):</strong></p></td><td><p><strong>9.0</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="2"><p><strong>TOTAL TABLET WEIGHT (excluding water):</strong></p></td><td><p><strong>309.0</strong></p></td><td><p><strong>--</strong></p></td></tr></tbody></table><p>$ Amount based on theoretical 100% potency of rosuvastatin calcium drug substance on the dried basis and typical water content(~1.8%). Actual quantity of rosuvastatin calcium is to be adjusted based on as is assay for Rosuvastatin. Lactose Monohydrate to be used for weight adjustment.</p><p>* Evaporated during coating process.</p><p>&nbsp;</p><p><strong>Table 4: Tablet composition of Apo-Rosuvastatin Tablets 40 mg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Component and Quality Standard (and Grade, if applicable)</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Function of Component</strong></p></td><td colspan="2"><p><strong>Quantity</strong></p></td></tr><tr><td><p><strong>mg/tablet</strong></p></td><td><p><strong>% w/w</strong></p></td></tr><tr><td colspan="4"><p><strong>CORE</strong></p></td></tr><tr><td><p>Rosuvastatin Calcium<sup>$</sup></p></td><td><p>Active</p></td><td><p>42.4</p></td><td><p>14.1</p></td></tr><tr><td><p>Lactose Monohydrate NF (Spray-Dried)<sup>$</sup></p></td><td><p>Diluent</p></td><td><p>179.3</p></td><td><p>59.8</p></td></tr><tr><td><p>Microcrystalline Cellulose NF (PH 102)</p></td><td><p>Diluent/ Binder</p></td><td><p>49.2</p></td><td><p>16.4</p></td></tr><tr><td><p>Crospovidone NF</p></td><td><p>Disintegrant</p></td><td><p>24.0</p></td><td><p>8.0</p></td></tr><tr><td><p>Magnesium Stearate NF</p></td><td><p>Lubricant</p></td><td><p>4.5</p></td><td><p>1.5</p></td></tr><tr><td><p>Colloidal Silicon Dioxide NF</p></td><td><p>Glidant</p></td><td><p>0.6</p></td><td><p>0.2</p></td></tr><tr><td colspan="2"><p><strong>Total Core</strong></p></td><td><p><strong>300</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="4"><p><strong>COATING</strong></p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 USP E5</p></td><td><p>Film Forming Polymer</p></td><td><p>2.70</p></td><td><p>30.00</p></td></tr><tr><td><p>Hydroxypropyl Cellulose NF Type LF</p></td><td><p>Film Forming Polymer</p></td><td><p>0.900</p></td><td><p>10.00</p></td></tr><tr><td><p>Polyethylene Glycol 8000 NF</p></td><td><p>Plasticizer</p></td><td><p>1.800</p></td><td><p>20.00</p></td></tr><tr><td><p>Titanium Dioxide USP</p></td><td><p>Opacifier</p></td><td><p>3.528</p></td><td><p>39.20</p></td></tr><tr><td><p>Red Ferric Oxide NF - Orange Shade</p></td><td><p>Colourant</p></td><td><p>0.072</p></td><td><p>0.8</p></td></tr><tr><td><p>Purified Water USP*</p></td><td><p>Solvent</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td colspan="2"><p><strong>Total Coating Solution (excluding water):</strong></p></td><td><p><strong>9.0</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td colspan="2"><p><strong>TOTAL TABLET WEIGHT (excluding water):</strong></p></td><td><p><strong>309.0</strong></p></td><td><p><strong>--</strong></p></td></tr></tbody></table><p>$ Amount based on theoretical 100% potency of rosuvastatin calcium drug substance on the dried basis and typical water content(~1.8%). Actual quantity of rosuvastatin calcium is to be adjusted based on as is assay for Rosuvastatin. Lactose Monohydrate to be used for weight adjustment.</p><p>* Evaporated during coating process.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from moisture. <strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Strength</strong></p></td><td><p><strong>Pack</strong><strong> Type/Size</strong></p></td><td><p><strong>Description</strong></p></td></tr><tr><td rowspan="2"><p>5 mg</p><p>10 mg</p><p>20 mg</p><p>40 mg</p></td><td rowspan="2"><p>Blister of 30&rsquo;s</p></td><td><p><strong>Plain Silver Foil</strong></p><p>Dull Silver on one side, shiny silver on other. Rolled material approximately 205 mm wide.</p></td></tr><tr><td><p><strong><u>Cold</u></strong><strong><u> Formable Silver Foil</u></strong></p><p>Dull Silver on one side, shiny silver on other. Rolled material approximately 205 mm wide.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 150 Signet Drive Toronto, Ontario Canada, M9L 1T9
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>